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ABSTRACT 
 
 
RUIWEI LIANG: EFFECT OF NF-κB HAPLOINSUFFICIENCY ON CRANIAL BONE HEALING 
(Under the direction of Lyndon F. Cooper) 
 
 
Bone defect is a major and challenging health concern. The treatment for bone defect aims 
to enhance bone regeneration, which is highly regulated by many molecular signaling 
pathways. Growing evidence suggested that proper inflammatory signaling was crucial for 
bone regeneration. Previous study showed that treatment of MSCs with expression of NF-
κB increased MSCs engraftment in damaged tissue. Previous work in our lab indicated a role 
of NF-κB on osteoblast differentiation during physiological bone development. The present 
study was designed to study role of NF-κB signaling in bone healing using genetically-
modified mouse with haploinsufficiency of p65 in osteoblasts. Here, we showed that mice 
with osteoprogenitor-specific NF-κB haploinsufficiency displayed reduced calvarial defect 
bone repair manifested by micro-CT and histological analysis. The progenitor cells from p65 
haploinsufficient mice demonstrated fewer CFU-OB colonies and decreased osteoblastic 
markers expression (Sp7, Alp and Bsp) in response to rhBMP2. Furthermore, rhBMP2 
mediated Smad phosphorylation was disrupted in the absence of sufficient p65 signal. 
Therefore, we concluded that NF-κB haploinsufficiency impairs bone repair by 
downregulation of BMP2 mediated canonical Smads signaling and osteogenic 
differentiation. The effect of inflammatory mediators on bone formation was 
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complex and yet to be elucidated. Based on our findings, we proposed a direct regulatory 
role of NF-κB in rhBMP2 mediated bone repair, suggesting that sufficient inflammatory cues 
are essential for bone regeneration. Uncovering the function of NF-κB in MSC-mediated 
repair will improve understanding of bone regeneration mechanism and provide a clue for 
bone regenerative therapy for treatment of bony defect.
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CHAPTER 1 
INTRODUCTION 
Bone defects and tissue regeneration 
Bony defect, a condition affecting the integrity of bone function, is a major and 
challenging problem for dental and orthopedic surgeons. Patients with bony defect suffer 
from detrimental impact to both physiological and psychological aspects of their lives. This 
condition represents a great economic burden, in the United States, as over 2.5 billion 
dollars are used for the treatment and care of bone defect patients each year. Moreover, 
this number is expected to double by 2020 (Amini et al., 2012; Baroli, 2009). Thus, there is 
high demand for affordable therapeutic options that can effectively treat this clinical 
condition. Current research aims to develop techniques that will enhance bone 
regeneration and promote bone repair. 
Bone is a dynamic tissue with an intrinsic capability to regenerate and remodel both 
during development and throughout life (Dimitriou et al., 2011; Einhorn, 1998). However, 
the self-repair capability of bone following injury is limited, and dependent on various 
factors such as age, gender, and injury severity. Previous literature demonstrates that 
successful spontaneous bone regeneration only occurs in children younger than 2 years old 
(Aghaloo et al., 2010). In many other clinical settings, where large bone defects caused by 
trauma, infections or surgery exist, the bone regeneration process is often compromised or 
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delayed (Szpalski et al., 2010). In such cases, strategies to restore bone regeneration and 
function are required. Understanding the bone regeneration process may help to identify 
the key factors that control bone healing, so that they may be targeted in future clinical 
applications. 
Bone healing is a complex but well-organized process, involving many cellular and 
molecular cascades. The process of bone healing resembles natural bone development. It 
has been described as three sequential and overlapping phases. 
Phase 1: Inflammatory phase 
The inflammation phase occurs immediately upon injury. This acute inflammatory 
response lasts for five to seven days in a limited, temporal manner. The onset of injury 
stimulates a series of signaling cascades, leading to a remarkable production of pro-
inflammatory cytokines (Mountziaris and Mikos, 2008; Mountziaris et al., 2011) that are 
secreted by inflammatory cells, macrophages, and cells of mesenchymal origin on the 
periosteum (Kon et al., 2001). The tremendous induction of cytokines suggests that the 
contributing cells include not only the local residents within sites of trauma, but also 
recruited cells from other distinct locations. The expression levels of interleukin-1 (IL-1), IL-
6, and tumor necrosis factor α (TNFα) peak at 24 hours following skeletal injury and then 
return to baseline at 72 hours (Kon et al., 2001). Other inflammatory cytokines observed in 
the initial inflammation phase include IL-11, IL-18, osteoprotegerin (OPG), receptor 
activator of NF-kB ligand (RANKL), and macrophage colony–stimulating factor (M-CSF) (Ai-
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Aql et al., 2008; Rundle et al., 2006). RANKL, OPG and M-CSF are vital regulators for 
osteocalstogenesis and osteoclast activity.  
The inflammation phase of bone healing is crucial for bone regeneration as it is 
responsible for initiating the healing cascades (Schmidt-Bleek et al., 2012). The pro-
inflammatory cytokines help to recruit mesenchymal stem cells and promote angiogenesis 
(Schmidt-Bleek et al., 2012). The transforming growth factor-beta (TGF-β) and vascular 
endothelial growth factors (VEGFs) synthesized by recruited MSCs and osteoblasts further 
stimulate stem cell proliferation and differentiation (Ai-Aql et al., 2008).  
The acute inflammation phase is critical for early bone repair and thus greatly affects 
the outcome of healing. Previous studies based on animal models suggest that the healing 
process is impaired in the absence of proper inflammatory signals (Gerstenfeld et al., 2003a; 
Katavic et al., 2003; Zhang et al., 2002). Anti-inflammatory medications, such as 
nonsteroidal anti-inflammatory drugs (NSAIDs), increase the risk of nonunion, malunion, 
and infections in patients treated for long bone fracture (Bhattacharyya et al., 2005; 
Jeffcoach et al., 2014).  
Phase 2: Bone formation phase 
A combination of intramembranous ossification and endochondral ossification 
processes occur subsequently from 7-14 days following injury. This phase is associated with 
elevated level of TGFs and BMPs, which promote bone regeneration via the differentiation 
and growth of recruited progenitor cells. VEGFs rise in accordance with enhanced 
angiogenesis and vascularization. Mesenchymal stem cells differentiate into an osteoblastic 
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lineage that produces bone matrix. Large amounts of extracellular matrix are deposited 
(Collagen, Aggrecan, OPN, BSP, etc.) at bone defects (Gerstenfeld et al., 2003b). The 
inflammatory response is absent during this phase. 
Phase 3: Bone remodeling phase 
Bone remodeling begins approximately 10 days, and can last anywhere from 28 days 
to 2 years, following injury (Ai-Aql et al., 2008; Khan et al., 2008; Kon et al., 2001). Pro-
inflammatory cytokines (IL-1, IL-6, TNFα) produced primarily by osteoblasts and 
hypertrophic chondrocytes reach a second peak. Along with factors that regulate osteoclast 
function (RANKL, OPG, M-CSF), these cytokines participate in replacing woven bone with 
mature lamellar bone.  
The major goal for treatment of bony defects is to induce and accelerate bone 
regeneration. Successful bone regeneration is achieved through bone formation by 
osteoblasts and bone resorption by osteoclasts. The differentiation of primitive 
mesenchymal stem cells into mature osteoblasts is referred to as osteoblastogenesis. It 
represents an essential component of bone healing and occurs in both bone development 
and post-natal bone repair. Bone regeneration shares a similar ossification mechanism with 
sequential expression of critical bone markers resembling the natural bone development. 
Understanding the process of bone development and identifying the signaling pathways 
involved in lineage specification of bone precursors will help to treat bone disorders that 
require bone regeneration. 
Bone development and homeostasis 
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Bone is one of the hardest tissues in the human body and provides mechanical 
support for the body and protection to the vital organs (brain, heart, etc.). In addition, it 
serves as a mineral reservoir for calcium and phosphorus. Bone is composed of organic 
components (bone matrix) including type I collagen and proteoglycans; and inorganic 
mineral composed of primarily hydroxyapatite (Allori et al., 2008b; Boskey and Posner, 
1984). At the cellular level, bone formation is accomplished by highly regulated cooperation 
of bone forming cells (osteoblasts), bone resorbing cells (osteoclasts) and osteocytes 
(Nakahama, 2010).  
Bone development initiates during the embryonic state through two distinct 
mechanisms: endochondral and intramembranous ossification. Endochondral ossification 
starts with a cartilaginous template formed by chondrocytes followed by replacement with 
mineralized matrix synthesized by osteoblasts. The majority of bone tissue, including long 
bones of both the axial and appendicular skeleton, are derived from this process (Javed et 
al., 2010). During intramembranous ossification, mesenchymal stem cells (MSCs) from 
condensed mesenchyme differentiate into osteoprogenitors and then develop into mature 
osteoblasts. Craniofacial bones (the flat bones of the skull and mandible) primarily develop 
from this mechanism (Franz-Odendaal, 2011; Javed et al., 2010). The maintenance of bone 
mass evolves through bone modeling and remodeling controlled by strictly regulated 
cooperation of osteoblasts and osteoclasts. Osteoblasts are bone forming cells that produce 
bone matrix (osteoid) and are responsible for matrix mineralization. In response to specific 
stimuli, bone marrow stromal cells or connective tissue mesenchymal stem cells can 
differentiate into osteoblasts postnatally (Tuan et al., 2003). 
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Bone undergoes continuous turnover, with a balance between bone formation by 
osteoblasts and bone resorption by osteoclasts. Osteoclasts are multi-nucleated cells that 
function in bone resorption.  Osteoclasts are differentiated from hematopoietic cells of the 
monocyte/macrophage lineage. They differ from osteoblasts, which are developed from 
mesenchymal stem cells. Characterized by the expression of tartrate-resistant acid 
phosphatase (TRAP), calcitonin receptors, p60c-src and vitronectin receptors, mature 
osteoclasts have the capacity to degrade bone tissue (Suda et al., 1997). Previous evidence 
has shown that the maturation of osteoclasts from the progenitors requires osteoblasts 
(Owens et al., 1996). Further investigation found that several factors secreted by 
osteoblasts are essential for osteoclast differentiation (Suda et al., 1999). These factors 
include M-CSF and RANKL. By association with their respective receptors on osteoclast 
precursors, M-CSF and RANKL promote osteoclastogenesis. This represents a positive 
regulatory role of osteoblast in osteoclast differentiation. In contrast, osteoblasts also 
produce OPG, a decoy receptor for RANK, thus inhibiting the RANKL-RANK binding (Hsu et 
al., 1999).  In this way, osteoblast negatively regulates osteoclast differentiation. The 
modulation of osteoclast differentiation by osteoblast indirectly affects bone resorption and 
homeostasis.   
The process of osteoblast differentiation can be characterized into three stages: 1) 
commitment of progenitors into the osteoblastic lineage; 2) proliferation of osteoblast 
precursors; and 3) bone matrix deposition, maturation and mineralization (Stein et al., 
1990). It is a well-orchestrated and highly regulated process, with stage-specific expression 
of many transcription factors. In bone tissue, multipotential mesenchymal stem cells 
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differentiate into osteochondroprogenitors that express Prx1 and Twist1 (ten Berge et al., 
1998; Yu et al., 2003). These early skeletal progenitors have the capacity to develop into 
either chondrogenic or osteoblastic lineages. Sox9 is the key transcription factor that drives 
chondrogenic differentiation (Mori-Akiyama et al., 2003). On the other hand, runx2 and 
osterix primarily direct the cell commitment into osteoblastic lineage (Harada and Rodan, 
2003).  The key transcription factors and several important osteogenic proteins involved in 
osteoblastogenesis are summarized below (Figure 1.1). 
Runx2 
Progressive osteoblast differentiation from early mesenchymal precursors requires 
tight modulation of transcription factors. Runx2 is the earliest transcriptional regulator, 
followed by osterix. Runx2 belongs to the Runx family, containing a runt DNA binding 
domain which is homologous with the Drosophila pair-rule gene runt (Komori, 2005). Runx2 
is widely accepted as the master regulator for osteoblast differentiation and plays a pivotal 
role during bone development. Runx2-null mice exhibit complete absence of both 
endochondral and intramembranous bone as a result of the lack of mature osteoblasts, and 
altered chondrocyte maturation as a result of hypertrophic chondrocytes. (Komori et al., 
1997; Otto et al., 1997).  
Runx2 expressing osteoprogenitors are able to differentiate into either osteoblasts 
or chondrocytes. Further differentiation from osteoprogenitors into functional mature 
osteoblasts that produce bone matrix requires osterix expression.  
Osterix 
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Osterix is a zinc finger-containing transcription factor belong to the Sp/XKLF family. 
Osterix functions immediately downstream of Runx2 (Javed et al., 2010). Previous literature 
demonstrates that osterix-deficient mice display normal Runx2 expression, while Runx2-null 
mice demonstrate no expression of osterix (Nakashima et al., 2002).  
Osterix is also essential for osteoblast differentiation and is expressed in all the 
osteoblasts throughout the embryonic bone development. Sp7 -/- mice show a similar bone 
phenotype to the Runx2 -/- mice, with a lack of mature differentiated osteoblasts in either 
intramembranous or endochondral ossification. However, different from Runx2 -/- mice, 
the osterix-null mice develop normal cartilage formation as well as terminally differentiated 
hypertrophic chondrocytes (Nakashima et al., 2002). This observation highlights a specific 
role of osterix in osteoblastic differentiation. 
Alkaline phosphatase (ALP) 
Once committed into osteoblastic cell lineages, the osteoprogenitors then go 
through a proliferative period before they differentiate into osteoblasts that synthesize 
extracellular matrix. Alkaline phosphatase is a membrane-bound enzyme and is expressed 
immediately after the proliferation period by osteoblasts. ALP is an early marker for 
osteoblasts during matrix maturation. Its expression is associated with maximal production 
of type I collagen (Javed et al., 2010).  
ALP also plays a pivotal role in the initiation of bone mineralization. The expression 
of ALP is regulated by many osteogenic signals including the BMP2-Runx2 axis as well as 
parathyroid hormone (PTH) and Wnt signaling pathways (Rawadi et al., 2003).  
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Bone sialoprotein (BSP)  
Osteoblasts are responsible for ECM production, maturation and mineralization. The 
ECM proteins in bone include mainly type I collagen, proteoglycans and other non-
collagenous proteins (bone sialoprotein, osteopontin, osteocalcin, etc.). These matrix 
proteins regulate osteoblast proliferation, differentiation and survival (Rodan and Noda, 
1991). BSP is a glycoprotein that belongs to the SIBLING (Small Integrin-binding Ligand N-
linked Glycoprotein) family. It is widely expressed by osteoblasts, hypertrophic 
chondrocytes and osteoclasts.  
BSP was shown to influence osteoblast differentiation and induce bone 
mineralization (Gordon et al., 2007). Mice lacking BSP displayed delayed long bone growth, 
mineralization and a decrease of bone markers including osteopontin (OPN) and osteocalcin 
(OCN) (Bouleftour et al., 2014). BSP deficient mice also demonstrated impaired bone 
healing, implicating a role for BSP in bone regeneration via bone formation and osteoclast 
activity (Malaval et al., 2009; Monfoulet et al., 2010).  
Osteocalcin (OCN) 
Osteocalcin, a vitamin K and vitamin D dependent non-collagenous protein, is also 
secreted by osteoblasts. It is not expressed in the early stages of osteoblast differentiation 
and, in fact, is the marker for the late phase of osteoblastogenesis (Bellows et al., 1999). 
Bgalap-expressing osteoblasts are usually recognized as mature osteoblasts. 
These osteogenic factors are essential for lineage specification and osteoblast 
differentiation. As a result, they are commonly referred to as bone markers. The 
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overlapping expression of bone markers directs the commitment, proliferation and 
differentiation of stem cells into osteoblasts. Evaluation of bone marker expression is often 
used to assess the differentiation stage of progenitor cells. The progression of stem cells 
into each differentiation stage requires many extracellular signals including growth factors 
(BMPs, FGFs, etc.), hormones (PTH, estrogen, etc.) and cytokines (interleukins) (Allori et al., 
2008a). In this sense, these osteogenic signals function in a stage-specific manner with a 
defined temporal expression profile.  
BMP2 in tissue engineering 
For the past several decades, tremendous efforts have been taken by scientists to 
develop effective treatment for critical-sized defects. In such cases where a large amount of 
bone is missing, spontaneous bone repair cannot occur. Therefore, the goal for treatment is 
to restore function by providing a local environment favorable for bone regeneration.  
Autografts have been utilized as a golden standard for treating bony defects in the 
clinical settings. Autografts are collected from patients’ own bone, primarily ileum or iliac 
crest, and then implanted into sites of bone defect. This technique yields a high possibility 
of success for bone regeneration due to high osteoconductivity, osteoinductivity and non-
immunogenic properties of autografts. However, it is always associated with considerable 
risks including donor site pain, post-surgery patient morbidity and high cost. (Amini et al., 
2012; Blokhuis et al., 2013). A common alternative to autografting is the application of 
allografting, which utilizes human cadaver bone. This method eliminates the surgical bone 
graft procedure that is necessary for autografting. The disadvantages associated with 
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allografts include the potential transmission of disease, immunogenic reaction and limited 
availability of cadaver bones. Due to the limitations of autografts and allografts, there is an 
increasing demand for the discovery of graft substitutes, which could replace, and resemble 
the form and properties of, natural bone (Giannoudis et al., 2005).  
In recent decades, researchers have focused on developing synthetic bone graft 
substitutes. An optimal substitute material is expected to provide adequate strength in 
response to mechanical load, and should gradually be absorbed during the process of new 
bone formation. The key properties that will determine the regenerative outcome of graft 
substitutes are: 1) a biocompatible and degradable scaffold carrier that serves as a template 
for bone cells to adhere, proliferate and differentiate (osteoconduction); 2) growth factors 
that stimulate progenitor differentiation into osteoblastic lineages (osteoinduction); and 3) 
existence of host cells or implanted cells to assist with bone repair (osteogenesis). However, 
an optimal material that fulfills all of the above requirements has yet to be developed.  
Due to this complexity of bone repair, an improved strategy using a combination of 
synthetic scaffolds, growth factors and cells holds the most promise as a tissue engineering 
application (Agarwal et al., 2009; Rahman et al., 2014). As researchers continue to gain a 
better understanding of the molecular pathways involved in bone healing, many relevant 
key factors have already been investigated in the lab and applied in clinical settings. Among 
the factors studied, bone morphogenetic proteins (BMPs), which belong to the transforming 
growth factor β (TGF-β) superfamily, have been heavily studied due to their strong 
osteoinductive capability. The TGF-β superfamily is a group of approximately 50 structurally 
and functionally related proteins. They participate in many biological processes such as 
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organogenesis, embryogenesis and wound healing (Attisano and Wrana, 2002; Miyazono, 
2000a). BMPs greatly impact bone development and healing. In 1965, BMPs were first 
identified as osteoinductive agents in demineralized bone matrix, and were later termed 
bone morphogenetic proteins by Urist (Urist, 1965; Urist and Strates, 1971). Currently, at 
least 20 BMPs have been recognized and described in humans as well as other species 
(Carreira et al., 2014).  
BMP2 transduces signals through direct binding to its serine-threonine kinase 
receptor complex (type I and type II receptors, BMPRI and BMPRII). This ligand-receptor 
interaction catalyzes the phosphorylation of downstream signaling transducers and 
activates the intracellular cascades (Carreira et al., 2014). In the canonical Smads pathway, 
receptor specific Smad proteins (R-Smads, Smad 1/5/8) are phosphorylated. Activated R-
Smads are then released from the cell membrane into the cytoplasm where they interact 
with Smads such as co-Smad and Smad 4. (Attisano and Wrana, 2002). The binding of R-
Smads with Smad4 enables the exposure of nucleus-imported sequences, allowing for the 
nuclear translocation of the R-Smads-Smad 4 complex and initiating transcriptional 
regulation (Kawabata et al., 1999; Miyazono, 2000b) (Figure 1.2).  
In the nucleus, the Smad heteromer modulates the transcription of major 
osteogenic genes including Runx2, Dlx5, Sp7, Alp and Bglap (Chen et al., 2012; Lee et al., 
2003; Luu et al., 2007; Nakashima et al., 2002). Microarray based gene profiling revealed 
that osteogenic BMP2 signaling induces activation of over 200 genes responsible for pre-
osteoblast proliferation and osteoblastic differentiation (Peng et al., 2003). This represents 
an important mechanism by which BMP2 regulates osteoblasts differentiation, bone 
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development and regeneration. Moreover, BMP2 is also a central mediator that can control 
the expression of other several other BMPs. (Edgar et al., 2007). 
Elevated BMP2 expression was observed as soon as 24 hours following bone injury, 
suggesting that it plays a role in the initiation of the bone healing process (Farhadieh et al., 
2004; Khanal et al., 2008; Kugimiya et al., 2005). BMP2 is found actively involved 
throughout the bone regeneration phase for at least 21 days after bone fracture (Bais et al., 
2009). The Smad 1/5/8 complex shares a similar expression pattern and localization with 
BMP2, as shown by immunohistochemical staining after osteotomy (Khanal et al., 2008).  
The importance of BMP2 in bone healing was addressed by the finding that mice 
with impaired BMP2 expression display normal bone development but defective bone 
healing (Tsuji et al., 2006). BMP2 is produced by osteoprogenitors, mesenchymal cells, 
chondrocytes and osteoblasts that either reside at, or are recruited to, the sites of injury. 
BMP2 induction upon bone injury was suggested to promote bone repair by: 1) initiating 
healing cascades and chemotaxis, and recruiting of mesenchymal stems cells; 2) activating 
other BMPs; and 3) activating many growth factors that control angiogenesis, cell 
proliferation and differentiation (Dimitriou et al., 2005).  
In the late 1980s, with the robust advancement of the recombinant DNA technique, 
human BMPs became available in large quantities (Wang et al., 1988). In 2002, the United 
States Food and Drug Administration (FDA) licensed rhBMP2 (InFuse Bone Graft, Medtronic 
Sofamor Danec USA, Inc.) as a clinical treatment of long bone open fractures, non-union 
fractures and spinal fusion. Since then, rhBMP2 has been extensively investigated for tissue 
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engineering applications in both experimental and clinical scenarios. For optimal effect, 
rhBMP2 is often delivered by carriers, which not only prolong protein retention, but also 
provide a platform for progenitor adhesion, proliferation and differentiation. Due to the 
desirable properties (biocompatibility, biodegradability, safety and being favorable for cell 
adhesion), absorbable collagen sponges (ACS) have become attractive carriers for tissue 
engineering.  
Local delivery of BMP2 by absorbable collagen carriers enhances bone healing and 
regeneration in both experimental and clinical scenarios (Kim et al., 2005; Lin et al., 2013; 
Simpson et al., 2006). The beneficial effect of rhBMP2/ACS has been applied to many clinical 
cases and has been reported to bridge critical-sized defects, promote fracture healing, 
induce spinal fusion and promote dental and craniofacial reconstruction (Chenard et al., 
2012; Geiger et al., 2003). Robust release of several pro-inflammatory cytokines (IL-1, IL-6, 
TNFα, etc.) is observed during both natural bone healing as well as rhBMP2 mediated bone 
regeneration (Gerstenfeld et al., 2003a; Lu et al., 2013). Interestingly, elevation of BMP2 
expression occurs and peaks in parallel with pro-inflammatory cytokines, at 24 hours post 
injury, and is sustained throughout the acute inflammation phase (Kon et al., 2001; 
Mountziaris and Mikos, 2008). BMP2 enhances the early inflammation phase, acting as a 
chemoattractant for immune cells, such as lymphocytes and macrophages (Cunningham et 
al., 1992). Moreover, BMP2 induces the expression of inflammatory mediators in various 
cell types including preosteoblasts (Akeel et al., 2012; Helbing et al., 2011).  
Inflammatory signals positively affect bone regeneration, representing one 
mechanism by which BMP2 participates in bone healing. This is supported by previous 
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findings that the osteoinductive capability of BMP2 is impaired in the absence of proper 
inflammatory signals (Katavic et al., 2003; Zhang et al., 2002). In addition, proinflammatory 
factors are proven to stimulate osteogenic differentiation of stem cells by increasing BMP2 
production (Fukui et al., 2003; Hess et al., 2009; Rifas, 2006). This evidence, taken together, 
implies a tight connection between the osteoinductivity of BMP2 and the inflammatory 
signaling pathway. On the other hand, this connection between BMP2 and inflammation is 
complex and not well understood, as many cases demonstrate a negative regenerative 
effect of rhBMP2. Excessive inflammation caused by systemic inflammatory disease or local 
infection impairs bone repair (Huang et al., 2014). High doses of rhBMP2 could cause 
adverse inflammatory responses such as soft tissue swelling, thereby diminishing the 
efficacy of rhBMP2-mediated repair (Lee et al., 2011). The exact role of inflammation on the 
osteoinductive capability of BMP2 remains unclear. Further understanding of this 
interaction will improve the current therapeutic strategy for skeletal repair. 
Although promising bone regenerative effects have been achieved using the rhBMP2 
based tissue engineering approach in the past several decades, an optimal healing process 
that mimics all of the healing cascades of natural bone repair has yet to be developed.  
NF-κB pathway and its involvement in bone biology 
The nuclear factor kappa B (NF-κB) transcription factor family is well known as a 
major component of innate immunity and the inflammatory response (Clohisy et al., 2004). 
In mammals, there are five NF-κB members including RelA (p65), RelB, c-Rel, p105/p50 (NF-
κB1) and p100/p52 (NF-κB2), which share an N-terminal Rel homology domain (RHD) 
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responsible for dimerization and DNA binding. The five monomers can form homodimers or 
heterodimers that function in gene expression regulation. Among those transcriptionally 
active dimers, the p65-p50 heterodimer is the most common form of NF-κB (Oeckinghaus 
and Ghosh, 2009; Vallabhapurapu and Karin, 2009). 
The NF-κB signaling is activated through two major pathways: the classical 
(canonical) pathway and alternative (non-canonical) pathway (Figure 1.3). These two 
pathways are different in many aspects including the participating NF-κB dimers activating 
signals as well as the biological functions. The classical pathway is induced by many 
extracellular cues such as receptor activator of the NF-κB ligand (RANKL) and TNFα. In an 
unstimulated state, NF-κB complexes are sequestered in the cytoplasm via association with 
IκB proteins (IκBα, IκBβ, and IκBɛ). The classical NF-κB signaling pathway is initiated upon 
activation of the IκB kinase complex (IKKα, IKKβ, IKKγ). The IKK catalytic complex 
phosphorylate IκB proteins for polyubiquitination and degradation in proteasomes, 
releasing the NF-κB dimer for nuclear translocation.  p65-p50 and cRel-p50 heterodimers 
mainly signal through the classical pathway (Hayden and Ghosh, 2008; Oeckinghaus and 
Ghosh, 2009). On the other hand, the alternative pathway is stimulated by only a subset of 
the TNF superfamily and is mainly involved in lymphoid development. NF-κB inducing kinase 
(NIK) is the key regulatory point which activates IKKα, leading to the processing of p100 into 
p52.  The p52-RelB heterodimer is the primary component in the alternative NF-κB signaling 
pathway (Bonizzi and Karin, 2004).  
NF-κB signaling is essential for embryogenesis and has an important role in 
endochondral ossification during bone development. The effect of NF-κB on osteoclasts and 
17 
 
related inflammatory bone disorders has been extensively investigated. Studies using a p50 
and p52 double knockout animal model demonstrated that these animals display 
osteopetrosis, with retarded growth and a significant decrease in osteoclast numbers 
(Iotsova et al., 1997). Other transgenic mice models with manipulated NF-κB elements also 
suggest the requirement of NF-κB signaling during osteoclastogenesis (Soysa and Alles, 
2009). Further investigation has determined the importance of NF-κB in osteoclast 
differentiation, survival and function by transcriptional regulation of osteoclast master 
genes including c-Fos, NFATc1, tartrate-resistant acid phosphatase (TRAP) and cathepsin K 
(Novack, 2011; Soysa and Alles, 2009).  
The role of NF-κB on osteoclasts is well defined. However, the effect of NF-κB on 
bone forming cells (osteoblasts) is relatively less explored. A role of NF-κB in osteoblast 
differentiation was suggested when Hess et al. reported that TNFα treatment/ p65 
activation positively affects osteogenic differentiation in human mesenchymal stromal cells 
through regulation of BMP2 expression (Hess et al., 2009). As a potent NF-κB activator, 
TNFα was also reported to induce osteogenic differentiation of human dental pulp stem 
cells, mesenchymal stem cells and human stem cells from apical papilla respectively 
through NF-κB signaling pathway (Cho et al., 2010; Feng et al., 2013; Li et al., 2014). In 
addition, NF-κB/p65 signaling activation facilitates BMP2-mediated chondrogenic 
differentiation during endochondral ossification (Caron et al., 2012). Two putative NF-κB 
response elements were found located in the promoter region of the BMP2 gene, 
implicating a direct regulatory mechanism of NF-κB in the BMP2 pathway (Feng et al., 
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2003). These findings indicate crosstalk between the NF-κB pathway and BMP2-mediated 
osteogenesis.  
In an attempt to investigate the precise role of NF-κB in osteogenesis, a transgenic 
animal model characterized by manipulation of the NF-κB function has been employed. 
Global knockout of p65 (RelA) leads to embryonic lethality of mice due to liver degeneration 
at 15-16 days of gestation caused by liver cell apoptosis (Beg et al., 1995). To circumvent the 
early lethality, strategies to generate conditional NF-κB knockout animals enabled the 
further investigation of NF-κB function on bone in vivo. A Cre-LoxP system has been widely 
used for tissue-specific elimination of target gene expression in mouse models. In mice 
harboring both the Cre transgene and a floxed target gene, Cre-recombinase mediates the 
gene deletion by cleaving the two specific 34-base LoxP sites that flank the target gene. A 
genetically modified Cre-recombinase transgene under the control of a tissue-specific 
promoter allows for deletion of a target gene in a specific tissue (Chambers, 1994).  
bglap2-IKK-DN mice with dominant negative IKKγ function in mature osteoblasts 
exhibit increased bone mineral density (BMD) and BV/TV at 2 and 4 weeks old (Chang et al., 
2009). In another study, Coll2-IKK2ca mice, in which IKKβ is constitutively active in 
chondrocytes, display impaired bone phenotype (Swarnkar et al., 2014). The promoter of 
bglap2 and Coll2 allows for the modulation of NF-κB signaling to occur specifically in mature 
osteoblasts and early skeletal progenitors, respectively. These two animal models both 
modulate NF-κB function by manipulating NF-κB regulatory elements (IKK complex). These 
findings suggest a negative role for NF-κB in bone formation, however, several other groups 
have suggested a positive effect of NF-κB on osteogenic differentiation of stem cells for 
19 
 
bone formation (Caron et al., 2012; Cho et al., 2010; Feng et al., 2013; Hess et al., 2009; Li et 
al., 2014). The current findings regarding the function of NF-κB on osteogenesis are 
controversial.  
The discrepancy of the results may lie in the difference of approaches that have 
been applied. One issue that comes with the transgenic mouse with manipulated NF-κB 
regulators is the difficulty to interpret the results. Since many NF-κB subunits share the 
same regulators, the indirect effect from other NF-κB components may contribute to the 
observed outcome. The strategies employed in previous studies include the local 
application of NF-κB inhibitors or activators and generation of virus expressing dominant 
negative or constitutive active NF-κB elements (Hess et al., 2009). Since NF-κB is a major 
inflammatory mediator, expressed by many cell types and not limited to bone cells, the 
treatment of NF-κB inhibitors and/or activators may affect other cells, indirectly influencing 
the outcome. An improved approach for investigating the direct role of NF-κB on 
osteogenesis will greatly improve the current knowledge and enhance accuracy and 
interpretation of future experiments. 
In sum, accumulating evidence has suggested a role for NF-κB in osteoblast function, 
in addition to its important role in osteocalstogenesis and bone resorption. A controlled 
balance between bone formation and resorption is critical for bone homeostasis as well as 
bone regeneration.  Previous studies have shown controversial results and the exact role of 
NF-κB in osteoblastogenesis remains unclear.  It was previously indicated that NF-κB may 
contribute to BMP2 mediated bone formation. As discussed earlier, inflammatory signals 
positively affect bone healing (Katavic et al., 2003; Zhang et al., 2002). There is a demanding 
20 
 
need to elucidate the precise function of NF-κB in bone homeostasis and healing, 
particularly as it relates to bone cells (osteoblasts). Deciphering the mechanism by which 
NF-κB affects bone healing in conjunction with BMP2 could provide a novel and efficient 
therapeutic target for clinical use. 
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Figure 1.1 Differentiation of primitive mesenchymal stem cells into osteoblasts.  
 
 
 
 
 
Adapted from Rodda et al. 2006  
  
22 
 
Figure 1.2 Signaling transduction of BMP2 pathway. 
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Figure 1.3 Canonical and non-canonical NF-κB signaling pathways in bone cells. 
 
  
24 
 
REFERNCES 
Agarwal, R., Williams, K., Umscheid, C.A., and Welch, W.C. (2009). Osteoinductive bone 
graft substitutes for lumbar fusion: a systematic review. Journal of neurosurgery Spine 11, 
729-740. 
Aghaloo, T., Cowan, C.M., Zhang, X., Freymiller, E., Soo, C., Wu, B., Ting, K., and Zhang, Z. 
(2010). The effect of NELL1 and bone morphogenetic protein-2 on calvarial bone 
regeneration. Journal of oral and maxillofacial surgery : official journal of the American 
Association of Oral and Maxillofacial Surgeons 68, 300-308. 
Ai-Aql, Z.S., Alagl, A.S., Graves, D.T., Gerstenfeld, L.C., and Einhorn, T.A. (2008). Molecular 
mechanisms controlling bone formation during fracture healing and distraction 
osteogenesis. Journal of dental research 87, 107-118. 
Akeel, S., El-Awady, A., Hussein, K., El-Refaey, M., Elsalanty, M., Sharawy, M., and Al-
Shabrawey, M. (2012). Recombinant bone morphogenetic protein-2 induces up-regulation 
of vascular endothelial growth factor and interleukin 6 in human pre-osteoblasts: role of 
reactive oxygen species. Archives of oral biology 57, 445-452. 
Allori, A.C., Sailon, A.M., and Warren, S.M. (2008a). Biological basis of bone formation, 
remodeling, and repair-part I: biochemical signaling molecules. Tissue engineering Part B, 
Reviews 14, 259-273. 
Allori, A.C., Sailon, A.M., and Warren, S.M. (2008b). Biological basis of bone formation, 
remodeling, and repair-part II: extracellular matrix. Tissue engineering Part B, Reviews 14, 
275-283. 
Amini, A.R., Laurencin, C.T., and Nukavarapu, S.P. (2012). Bone tissue engineering: recent 
advances and challenges. Critical reviews in biomedical engineering 40, 363-408. 
Attisano, L., and Wrana, J.L. (2002). Signal transduction by the TGF-beta superfamily. 
Science 296, 1646-1647. 
Bais, M., McLean, J., Sebastiani, P., Young, M., Wigner, N., Smith, T., Kotton, D.N., Einhorn, 
T.A., and Gerstenfeld, L.C. (2009). Transcriptional analysis of fracture healing and the 
induction of embryonic stem cell-related genes. PloS one 4, e5393. 
25 
 
Baroli, B. (2009). From natural bone grafts to tissue engineering therapeutics: Brainstorming 
on pharmaceutical formulative requirements and challenges. Journal of pharmaceutical 
sciences 98, 1317-1375. 
Beg, A.A., Sha, W.C., Bronson, R.T., Ghosh, S., and Baltimore, D. (1995). Embryonic lethality 
and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376, 167-
170. 
Bellows, C.G., Reimers, S.M., and Heersche, J.N. (1999). Expression of mRNAs for type-I 
collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic 
differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell and tissue research 
297, 249-259. 
Bhattacharyya, T., Levin, R., Vrahas, M.S., and Solomon, D.H. (2005). Nonsteroidal 
antiinflammatory drugs and nonunion of humeral shaft fractures. Arthritis and rheumatism 
53, 364-367. 
Blokhuis, T.J., Calori, G.M., and Schmidmaier, G. (2013). Autograft versus BMPs for the 
treatment of non-unions: what is the evidence? Injury 44 Suppl 1, S40-42. 
Bonizzi, G., and Karin, M. (2004). The two NF-kappaB activation pathways and their role in 
innate and adaptive immunity. Trends in immunology 25, 280-288. 
Boskey, A.L., and Posner, A.S. (1984). Bone structure, composition, and mineralization. The 
Orthopedic clinics of North America 15, 597-612. 
Bouleftour, W., Boudiffa, M., Wade-Gueye, N.M., Bouet, G., Cardelli, M., Laroche, N., 
Vanden-Bossche, A., Thomas, M., Bonnelye, E., Aubin, J.E., et al. (2014). Skeletal 
development of mice lacking bone sialoprotein (BSP)--impairment of long bone growth and 
progressive establishment of high trabecular bone mass. PloS one 9, e95144. 
Caron, M.M., Emans, P.J., Surtel, D.A., Cremers, A., Voncken, J.W., Welting, T.J., and van 
Rhijn, L.W. (2012). Activation of NF-kappaB/p65 facilitates early chondrogenic 
differentiation during endochondral ossification. PloS one 7, e33467. 
Carreira, A.C., Lojudice, F.H., Halcsik, E., Navarro, R.D., Sogayar, M.C., and Granjeiro, J.M. 
(2014). Bone morphogenetic proteins: facts, challenges, and future perspectives. Journal of 
dental research 93, 335-345. 
26 
 
Chambers, C.A. (1994). TKO'ed: lox, stock and barrel. BioEssays : news and reviews in 
molecular, cellular and developmental biology 16, 865-868. 
Chang, J., Wang, Z., Tang, E., Fan, Z., McCauley, L., Franceschi, R., Guan, K., Krebsbach, P.H., 
and Wang, C.Y. (2009). Inhibition of osteoblastic bone formation by nuclear factor-kappaB. 
Nature medicine 15, 682-689. 
Chen, G., Deng, C., and Li, Y.P. (2012). TGF-beta and BMP signaling in osteoblast 
differentiation and bone formation. International journal of biological sciences 8, 272-288. 
Chenard, K.E., Teven, C.M., He, T.C., and Reid, R.R. (2012). Bone morphogenetic proteins in 
craniofacial surgery: current techniques, clinical experiences, and the future of personalized 
stem cell therapy. Journal of biomedicine & biotechnology 2012, 601549. 
Cho, H.H., Shin, K.K., Kim, Y.J., Song, J.S., Kim, J.M., Bae, Y.C., Kim, C.D., and Jung, J.S. (2010). 
NF-kappaB activation stimulates osteogenic differentiation of mesenchymal stem cells 
derived from human adipose tissue by increasing TAZ expression. Journal of cellular 
physiology 223, 168-177. 
Clohisy, J.C., Hirayama, T., Frazier, E., Han, S.K., and Abu-Amer, Y. (2004). NF-kB signaling 
blockade abolishes implant particle-induced osteoclastogenesis. Journal of orthopaedic 
research : official publication of the Orthopaedic Research Society 22, 13-20. 
Cunningham, N.S., Paralkar, V., and Reddi, A.H. (1992). Osteogenin and recombinant bone 
morphogenetic protein 2B are chemotactic for human monocytes and stimulate 
transforming growth factor beta 1 mRNA expression. Proceedings of the National Academy 
of Sciences of the United States of America 89, 11740-11744. 
Dimitriou, R., Jones, E., McGonagle, D., and Giannoudis, P.V. (2011). Bone regeneration: 
current concepts and future directions. BMC medicine 9, 66. 
Dimitriou, R., Tsiridis, E., and Giannoudis, P.V. (2005). Current concepts of molecular aspects 
of bone healing. Injury 36, 1392-1404. 
Edgar, C.M., Chakravarthy, V., Barnes, G., Kakar, S., Gerstenfeld, L.C., and Einhorn, T.A. 
(2007). Autogenous regulation of a network of bone morphogenetic proteins (BMPs) 
mediates the osteogenic differentiation in murine marrow stromal cells. Bone 40, 1389-
1398. 
27 
 
Einhorn, T.A. (1998). The cell and molecular biology of fracture healing. Clinical 
orthopaedics and related research, S7-21. 
Farhadieh, R.D., Gianoutsos, M.P., Yu, Y., and Walsh, W.R. (2004). The role of bone 
morphogenetic proteins BMP-2 and BMP-4 and their related postreceptor signaling system 
(Smads) in distraction osteogenesis of the mandible. The Journal of craniofacial surgery 15, 
714-718. 
Feng, J.Q., Xing, L., Zhang, J.H., Zhao, M., Horn, D., Chan, J., Boyce, B.F., Harris, S.E., Mundy, 
G.R., and Chen, D. (2003). NF-kappaB specifically activates BMP-2 gene expression in growth 
plate chondrocytes in vivo and in a chondrocyte cell line in vitro. The Journal of biological 
chemistry 278, 29130-29135. 
Feng, X., Feng, G., Xing, J., Shen, B., Li, L., Tan, W., Xu, Y., Liu, S., Liu, H., Jiang, J., et al. 
(2013). TNF-alpha triggers osteogenic differentiation of human dental pulp stem cells via 
the NF-kappaB signalling pathway. Cell biology international 37, 1267-1275. 
Franz-Odendaal, T.A. (2011). Induction and patterning of intramembranous bone. Frontiers 
in bioscience 16, 2734-2746. 
Fukui, N., Zhu, Y., Maloney, W.J., Clohisy, J., and Sandell, L.J. (2003). Stimulation of BMP-2 
expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic 
chondrocytes. The Journal of bone and joint surgery American volume 85-A Suppl 3, 59-66. 
Geiger, M., Li, R.H., and Friess, W. (2003). Collagen sponges for bone regeneration with 
rhBMP-2. Advanced drug delivery reviews 55, 1613-1629. 
Gerstenfeld, L.C., Cho, T.J., Kon, T., Aizawa, T., Tsay, A., Fitch, J., Barnes, G.L., Graves, D.T., 
and Einhorn, T.A. (2003a). Impaired fracture healing in the absence of TNF-alpha signaling: 
the role of TNF-alpha in endochondral cartilage resorption. Journal of bone and mineral 
research : the official journal of the American Society for Bone and Mineral Research 18, 
1584-1592. 
Gerstenfeld, L.C., Cullinane, D.M., Barnes, G.L., Graves, D.T., and Einhorn, T.A. (2003b). 
Fracture healing as a post-natal developmental process: molecular, spatial, and temporal 
aspects of its regulation. Journal of cellular biochemistry 88, 873-884. 
28 
 
Giannoudis, P.V., Dinopoulos, H., and Tsiridis, E. (2005). Bone substitutes: an update. Injury 
36 Suppl 3, S20-27. 
Gordon, J.A., Tye, C.E., Sampaio, A.V., Underhill, T.M., Hunter, G.K., and Goldberg, H.A. 
(2007). Bone sialoprotein expression enhances osteoblast differentiation and matrix 
mineralization in vitro. Bone 41, 462-473. 
Harada, S., and Rodan, G.A. (2003). Control of osteoblast function and regulation of bone 
mass. Nature 423, 349-355. 
Hayden, M.S., and Ghosh, S. (2008). Shared principles in NF-kappaB signaling. Cell 132, 344-
362. 
Helbing, T., Rothweiler, R., Ketterer, E., Goetz, L., Heinke, J., Grundmann, S., Duerschmied, 
D., Patterson, C., Bode, C., and Moser, M. (2011). BMP activity controlled by BMPER 
regulates the proinflammatory phenotype of endothelium. Blood 118, 5040-5049. 
Hess, K., Ushmorov, A., Fiedler, J., Brenner, R.E., and Wirth, T. (2009). TNFalpha promotes 
osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB 
signaling pathway. Bone 45, 367-376. 
Hsu, H., Lacey, D.L., Dunstan, C.R., Solovyev, I., Colombero, A., Timms, E., Tan, H.L., Elliott, 
G., Kelley, M.J., Sarosi, I., et al. (1999). Tumor necrosis factor receptor family member RANK 
mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. 
Proceedings of the National Academy of Sciences of the United States of America 96, 3540-
3545. 
Huang, R.L., Yuan, Y., Zou, G.M., Liu, G., Tu, J., and Li, Q. (2014). LPS-stimulated 
inflammatory environment inhibits BMP-2-induced osteoblastic differentiation through 
crosstalk between TLR4/MyD88/NF-kappaB and BMP/Smad signaling. Stem cells and 
development 23, 277-289. 
Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., and Bravo, R. (1997). Osteopetrosis in 
mice lacking NF-kappaB1 and NF-kappaB2. Nature medicine 3, 1285-1289. 
Javed, A., Chen, H., and Ghori, F.Y. (2010). Genetic and transcriptional control of bone 
formation. Oral and maxillofacial surgery clinics of North America 22, 283-293, v. 
29 
 
Jeffcoach, D.R., Sams, V.G., Lawson, C.M., Enderson, B.L., Smith, S.T., Kline, H., Barlow, P.B., 
Wylie, D.R., Krumenacker, L.A., McMillen, J.C., et al. (2014). Nonsteroidal anti-inflammatory 
drugs' impact on nonunion and infection rates in long-bone fractures. The journal of trauma 
and acute care surgery 76, 779-783. 
Katavic, V., Grcevic, D., Lukic, I.K., Vucenik, V., Kovacic, N., Kalajzic, I., and Marusic, A. 
(2003). Non-functional Fas ligand increases the formation of cartilage early in the 
endochondral bone induction by rhBMP-2. Life sciences 74, 13-28. 
Kawabata, M., Imamura, T., Inoue, H., Hanai, J., Nishihara, A., Hanyu, A., Takase, M., 
Ishidou, Y., Udagawa, Y., Oeda, E., et al. (1999). Intracellular signaling of the TGF-beta 
superfamily by Smad proteins. Annals of the New York Academy of Sciences 886, 73-82. 
Khan, S.N., Solaris, J., Ramsey, K.E., Yang, X., Bostrom, M.P., Stephan, D., and Daluiski, A. 
(2008). Identification of novel gene expression in healing fracture callus tissue by DNA 
microarray. HSS journal : the musculoskeletal journal of Hospital for Special Surgery 4, 149-
160. 
Khanal, A., Yoshioka, I., Tominaga, K., Furuta, N., Habu, M., and Fukuda, J. (2008). The BMP 
signaling and its Smads in mandibular distraction osteogenesis. Oral diseases 14, 347-355. 
Kim, C.S., Kim, J.I., Kim, J., Choi, S.H., Chai, J.K., Kim, C.K., and Cho, K.S. (2005). Ectopic bone 
formation associated with recombinant human bone morphogenetic proteins-2 using 
absorbable collagen sponge and beta tricalcium phosphate as carriers. Biomaterials 26, 
2501-2507. 
Komori, T. (2005). Regulation of skeletal development by the Runx family of transcription 
factors. Journal of cellular biochemistry 95, 445-453. 
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, 
R.T., Gao, Y.H., Inada, M., et al. (1997). Targeted disruption of Cbfa1 results in a complete 
lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755-764. 
Kon, T., Cho, T.J., Aizawa, T., Yamazaki, M., Nooh, N., Graves, D., Gerstenfeld, L.C., and 
Einhorn, T.A. (2001). Expression of osteoprotegerin, receptor activator of NF-kappaB ligand 
(osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. 
Journal of bone and mineral research : the official journal of the American Society for Bone 
and Mineral Research 16, 1004-1014. 
30 
 
Kugimiya, F., Kawaguchi, H., Kamekura, S., Chikuda, H., Ohba, S., Yano, F., Ogata, N., 
Katagiri, T., Harada, Y., Azuma, Y., et al. (2005). Involvement of endogenous bone 
morphogenetic protein (BMP) 2 and BMP6 in bone formation. The Journal of biological 
chemistry 280, 35704-35712. 
Lee, K.B., Murray, S.S., Taghavi, C.E., Song, K.J., Brochmann, E.J., Johnson, J.S., Keorochana, 
G., Liao, J.C., and Wang, J.C. (2011). Bone morphogenetic protein-binding peptide reduces 
the inflammatory response to recombinant human bone morphogenetic protein-2 and 
recombinant human bone morphogenetic protein-7 in a rodent model of soft-tissue 
inflammation. The spine journal : official journal of the North American Spine Society 11, 
568-576. 
Lee, M.H., Kim, Y.J., Kim, H.J., Park, H.D., Kang, A.R., Kyung, H.M., Sung, J.H., Wozney, J.M., 
Kim, H.J., and Ryoo, H.M. (2003). BMP-2-induced Runx2 expression is mediated by Dlx5, and 
TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 
expression. The Journal of biological chemistry 278, 34387-34394. 
Li, J., Yan, M., Wang, Z., Jing, S., Li, Y., Liu, G., Yu, J., and Fan, Z. (2014). Effects of canonical 
NF-kappaB signaling pathway on the proliferation and odonto/osteogenic differentiation of 
human stem cells from apical papilla. BioMed research international 2014, 319651. 
Lin, C.Y., Chang, Y.H., Li, K.C., Lu, C.H., Sung, L.Y., Yeh, C.L., Lin, K.J., Huang, S.F., Yen, T.C., 
and Hu, Y.C. (2013). The use of ASCs engineered to express BMP2 or TGF-beta3 within 
scaffold constructs to promote calvarial bone repair. Biomaterials 34, 9401-9412. 
Lu, Z., Wang, G., Dunstan, C.R., Chen, Y., Lu, W.Y., Davies, B., and Zreiqat, H. (2013). 
Activation and promotion of adipose stem cells by tumour necrosis factor-alpha 
preconditioning for bone regeneration. Journal of cellular physiology 228, 1737-1744. 
Luu, H.H., Song, W.X., Luo, X., Manning, D., Luo, J., Deng, Z.L., Sharff, K.A., Montag, A.G., 
Haydon, R.C., and He, T.C. (2007). Distinct roles of bone morphogenetic proteins in 
osteogenic differentiation of mesenchymal stem cells. Journal of orthopaedic research : 
official publication of the Orthopaedic Research Society 25, 665-677. 
Malaval, L., Monfoulet, L., Fabre, T., Pothuaud, L., Bareille, R., Miraux, S., Thiaudiere, E., 
Raffard, G., Franconi, J.M., Lafage-Proust, M.H., et al. (2009). Absence of bone sialoprotein 
(BSP) impairs cortical defect repair in mouse long bone. Bone 45, 853-861. 
31 
 
Miyazono, K. (2000a). Positive and negative regulation of TGF-beta signaling. Journal of cell 
science 113 ( Pt 7), 1101-1109. 
Miyazono, K. (2000b). TGF-beta signaling by Smad proteins. Cytokine & growth factor 
reviews 11, 15-22. 
Monfoulet, L., Malaval, L., Aubin, J.E., Rittling, S.R., Gadeau, A.P., Fricain, J.C., and 
Chassande, O. (2010). Bone sialoprotein, but not osteopontin, deficiency impairs the 
mineralization of regenerating bone during cortical defect healing. Bone 46, 447-452. 
Mori-Akiyama, Y., Akiyama, H., Rowitch, D.H., and de Crombrugghe, B. (2003). Sox9 is 
required for determination of the chondrogenic cell lineage in the cranial neural crest. 
Proceedings of the National Academy of Sciences of the United States of America 100, 
9360-9365. 
Mountziaris, P.M., and Mikos, A.G. (2008). Modulation of the inflammatory response for 
enhanced bone tissue regeneration. Tissue engineering Part B, Reviews 14, 179-186. 
Mountziaris, P.M., Spicer, P.P., Kasper, F.K., and Mikos, A.G. (2011). Harnessing and 
modulating inflammation in strategies for bone regeneration. Tissue engineering Part B, 
Reviews 17, 393-402. 
Nakahama, K. (2010). Cellular communications in bone homeostasis and repair. Cellular and 
molecular life sciences : CMLS 67, 4001-4009. 
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J.M., Behringer, R.R., and de 
Crombrugghe, B. (2002). The novel zinc finger-containing transcription factor osterix is 
required for osteoblast differentiation and bone formation. Cell 108, 17-29. 
Novack, D.V. (2011). Role of NF-kappaB in the skeleton. Cell research 21, 169-182. 
Oeckinghaus, A., and Ghosh, S. (2009). The NF-kappaB family of transcription factors and its 
regulation. Cold Spring Harbor perspectives in biology 1, a000034. 
Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C., Rosewell, I.R., Stamp, G.W., 
Beddington, R.S., Mundlos, S., Olsen, B.R., et al. (1997). Cbfa1, a candidate gene for 
32 
 
cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone 
development. Cell 89, 765-771. 
Owens, J.M., Gallagher, A.C., and Chambers, T.J. (1996). Bone cells required for osteoclastic 
resorption but not for osteoclastic differentiation. Biochemical and biophysical research 
communications 222, 225-229. 
Peng, Y., Kang, Q., Cheng, H., Li, X., Sun, M.H., Jiang, W., Luu, H.H., Park, J.Y., Haydon, R.C., 
and He, T.C. (2003). Transcriptional characterization of bone morphogenetic proteins 
(BMPs)-mediated osteogenic signaling. Journal of cellular biochemistry 90, 1149-1165. 
Rahman, C.V., Ben-David, D., Dhillon, A., Kuhn, G., Gould, T.W., Muller, R., Rose, F.R., 
Shakesheff, K.M., and Livne, E. (2014). Controlled release of BMP-2 from a sintered polymer 
scaffold enhances bone repair in a mouse calvarial defect model. Journal of tissue 
engineering and regenerative medicine 8, 59-66. 
Rawadi, G., Vayssiere, B., Dunn, F., Baron, R., and Roman-Roman, S. (2003). BMP-2 controls 
alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. 
Journal of bone and mineral research : the official journal of the American Society for Bone 
and Mineral Research 18, 1842-1853. 
Rifas, L. (2006). T-cell cytokine induction of BMP-2 regulates human mesenchymal stromal 
cell differentiation and mineralization. Journal of cellular biochemistry 98, 706-714. 
Rodan, G.A., and Noda, M. (1991). Gene expression in osteoblastic cells. Critical reviews in 
eukaryotic gene expression 1, 85-98. 
Rundle, C.H., Wang, H., Yu, H., Chadwick, R.B., Davis, E.I., Wergedal, J.E., Lau, K.H., Mohan, 
S., Ryaby, J.T., and Baylink, D.J. (2006). Microarray analysis of gene expression during the 
inflammation and endochondral bone formation stages of rat femur fracture repair. Bone 
38, 521-529. 
Schmidt-Bleek, K., Schell, H., Schulz, N., Hoff, P., Perka, C., Buttgereit, F., Volk, H.D., Lienau, 
J., and Duda, G.N. (2012). Inflammatory phase of bone healing initiates the regenerative 
healing cascade. Cell and tissue research 347, 567-573. 
33 
 
Simpson, A.H., Mills, L., and Noble, B. (2006). The role of growth factors and related agents 
in accelerating fracture healing. The Journal of bone and joint surgery British volume 88, 
701-705. 
Soysa, N.S., and Alles, N. (2009). NF-kappaB functions in osteoclasts. Biochemical and 
biophysical research communications 378, 1-5. 
Stein, G.S., Lian, J.B., and Owen, T.A. (1990). Relationship of cell growth to the regulation of 
tissue-specific gene expression during osteoblast differentiation. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology 4, 3111-3123. 
Suda, T., Nakamura, I., Jimi, E., and Takahashi, N. (1997). Regulation of osteoclast function. 
Journal of bone and mineral research : the official journal of the American Society for Bone 
and Mineral Research 12, 869-879. 
Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T., and Martin, T.J. (1999). 
Modulation of osteoclast differentiation and function by the new members of the tumor 
necrosis factor receptor and ligand families. Endocrine reviews 20, 345-357. 
Swarnkar, G., Zhang, K., Mbalaviele, G., Long, F., and Abu-Amer, Y. (2014). Constitutive 
activation of IKK2/NF-kappaB impairs osteogenesis and skeletal development. PloS one 9, 
e91421. 
Szpalski, C., Barr, J., Wetterau, M., Saadeh, P.B., and Warren, S.M. (2010). Cranial bone 
defects: current and future strategies. Neurosurgical focus 29, E8. 
ten Berge, D., Brouwer, A., Korving, J., Martin, J.F., and Meijlink, F. (1998). Prx1 and Prx2 in 
skeletogenesis: roles in the craniofacial region, inner ear and limbs. Development 125, 
3831-3842. 
Tsuji, K., Bandyopadhyay, A., Harfe, B.D., Cox, K., Kakar, S., Gerstenfeld, L., Einhorn, T., 
Tabin, C.J., and Rosen, V. (2006). BMP2 activity, although dispensable for bone formation, is 
required for the initiation of fracture healing. Nature genetics 38, 1424-1429. 
Tuan, R.S., Boland, G., and Tuli, R. (2003). Adult mesenchymal stem cells and cell-based 
tissue engineering. Arthritis research & therapy 5, 32-45. 
34 
 
Urist, M.R. (1965). Bone: formation by autoinduction. Science 150, 893-899. 
Urist, M.R., and Strates, B.S. (1971). Bone morphogenetic protein. Journal of dental 
research 50, 1392-1406. 
Vallabhapurapu, S., and Karin, M. (2009). Regulation and function of NF-kappaB 
transcription factors in the immune system. Annual review of immunology 27, 693-733. 
Wang, E.A., Rosen, V., Cordes, P., Hewick, R.M., Kriz, M.J., Luxenberg, D.P., Sibley, B.S., and 
Wozney, J.M. (1988). Purification and characterization of other distinct bone-inducing 
factors. Proceedings of the National Academy of Sciences of the United States of America 
85, 9484-9488. 
Yu, K., Xu, J., Liu, Z., Sosic, D., Shao, J., Olson, E.N., Towler, D.A., and Ornitz, D.M. (2003). 
Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the 
regulation of osteoblast function and bone growth. Development 130, 3063-3074. 
Zhang, X., Schwarz, E.M., Young, D.A., Puzas, J.E., Rosier, R.N., and O'Keefe, R.J. (2002). 
Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage 
and is critically involved in bone repair. The Journal of clinical investigation 109, 1405-1415. 
 
35 
 
CHAPTER 2 
EFFECT OF NF-κB HAPLOINSUFFICIENCY ON CALVARIAL BONE HEALING 
INTRODUCTION 
Critical sized bony defect caused by congenital disorders, trauma, tumors or 
infection remains a challenge for dental and orthopedic surgeons and represents a great 
economic burden to health resources (Amini et al., 2012; Baroli, 2009). The treatment for 
such clinical conditions requires enhancement and acceleration of bone regeneration with 
the application of bone grafts (Pneumaticos et al., 2010; Tevlin et al., 2014). To avoid the 
intrinsic shortcoming of natural bone grafts (i.e donor site morbidity, immunogenic 
property, pain, etc.), synthetic bone graft substitutes using biocompatible scaffold carrier, 
with osteoinductive agents including BMPs and other growth factors, have been developed 
(Amini et al., 2012; Chenard et al., 2012). 
Bone morphogenic protein 2 (BMP2) is a growth factor that belongs to the 
transforming growth factor-β superfamily. At the cellular level, BMP2 triggers the 
phosphorylation of downstream Smad1, 5 and 8, leading to the transcriptional regulation of 
major osteogenic markers such as Runx2, Sp7, Alp, Bsp and Bglap (Chen et al., 1997; Luu et 
al., 2007; Nakashima et al., 2002). As a potent and promising osteogenic/osteoinducing 
factor, the Food and Drug Administration (FDA) approved BMP2 for the treatment of non-
union fractures and spinal fusion in 2002. Both early clinical trial, as well as basic science
36 
 
research experiments using animal models, showed improved bone formation and healing 
following local delivery of BMP2 by an absorbable collagen carrier (Kim et al., 2005; Lin et 
al., 2013; Simpson et al., 2006). BMP2-mediated bone regeneration involves in an initial 
inflammatory response associated with the production of cytokines such as tumor necrosis 
factor-α (TNFα) and interleukin-6 (IL-6) (Gerstenfeld et al., 2003). In vitro studies revealed 
that BMP2 induces expression of inflammatory mediators in various cell types including 
preosteoblasts (Akeel et al., 2012; Helbing et al., 2011). Inflammatory signals are crucial for 
the recruitment and subsequent differentiation of stem and progenitor cells, reflecting a 
signaling mechanism through which BMP2 promotes bone regeneration. Furthermore, the 
osteoinductive capability of BMP2 is impaired in the absence of proper inflammatory signals 
(Katavic et al., 2003; Zhang et al., 2002).  
Nuclear factor kappa B (NF-κB) is recognized as a master regulator for the immune 
system and inflammatory response. The NF-κB family is comprised of transcription factors 
that mediate many biological activities including cell proliferation, survival and apoptosis (Li 
and Verma, 2002). The NF-κB family consists of 5 proteins in mammalian cells: RelA (p65), 
RelB, c-Rel, p50 and p52. These members all share an N-terminal Rel homology domain 
which is responsible for dimerization and DNA binding. The p65-p50 heterodimer is the 
most common form of NF-κB in mammals (Oeckinghaus and Ghosh, 2009; Vallabhapurapu 
and Karin, 2009). In unstimulated cells, inactive NF-κB complexes remain in the cytoplasm in 
association with IκB proteins (IκBα, IκBβ and IκBɛ). Upon activation, IκB proteins are 
phosphorylated by the IκB kinase complex (IKKα, IKKβ and IKKγ), resulting in the release of 
the NF-κB dimers into the nucleus. Many pro-inflammatory factors such as receptor 
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activator of NF-κB ligand (RANKL) and TNFα are able to induce NF-κB activation through the 
classical pathway, which requires the p65-p50 and cRel-p50 heterodimers. (Hayden and 
Ghosh, 2008; Oeckinghaus and Ghosh, 2009).  
NF-κB signaling is required for bone development. Its interaction with bone 
resorbing cells (osteoclasts) and role in relevant inflammatory bone disorders has been 
extensively investigated (Abu-Amer, 2013). Growing evidence suggests that NF-κB, as a vital 
inflammatory mediator, is vital for osteoblastic regulation and osteogenesis (Caron et al., 
2012; Cho et al., 2010; Hess et al., 2009). NF-κB/p65 signaling activation facilitates BMP2-
mediated chondrogenic differentiation during endochondral ossification (Caron et al., 
2012). Moreover, TNFα treatment and p65 activation positively influences osteogenic 
differentiation of human mesenchymal stromal cells (hMSCs) via the regulation of BMP2 
expression (Hess et al., 2009). These findings indicate an interaction between NF-κB 
mediated inflammatory signals and BMP2-induced bone formation and repair. The precise 
role of NF-κB in the context of bone forming cells (osteoblasts), however, remains unclear. 
Moreover, little is known regarding the role of the NF-κB signaling pathway in the 
osteoinductivity of BMP2 during bone healing. 
In the present study, we sought to investigate the interplay between NF-κB signaling 
and BMP2 mediated bone repair in a critical size calvarial defect model using a genetically 
modified mouse model. Given the fact that the global deletion of p65, a major NF-κB 
component, is embryonic lethal, we utilized a Cre/Loxp strategy to generate transgenic mice 
with a NF-κB deficiency restricted to bone tissue. By crossing the p65 floxed mice with Osx-
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Cre mice, we obtained mice with a p65 haploinsufficiency in osteoblastic cell lineages. p65 
expression was regulated by the Sp7 promoter. 
Uncovering the function of NF-κB during BMP2-mediated bone repair will enhance 
the understanding of bone regeneration mechanisms, thereby providing new therapeutic 
targets for improved treatment that promotes integrated skeletal regeneration. 
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Materials and Methods 
Mice 
p65-floxed mice were crossed with Osterix-Cre mice (Osx-Cre) in order to generate 
mice with an osteoblast-restricted p65 ablation (p65fl/+Osx-Cre) (see Figure 2.1). p65 floxed 
mice (p65fl/fl) in which exons 5-8 of p65 were flanked with loxp constructs were provided by 
Dr. Albert S Baldwin, University of North Carolina at Chapel Hill (Steinbrecher et al., 2008). 
Osterix-Cre mice (Osx-Cre) which express a GFP fused Cre recombinase gene downstream of 
the Sp7 promoter were purchased from the Jackson Laboratory (Bar Harbor, ME). The 
phenotype of Osx-Cre mice has been described previously (Rodda and McMahon, 2006). All 
animals were on the C57BL/6 background.  
Genotyping of mice was performed using PCR of genomic DNA, which was isolated 
from tail samples taken from mice. Primer sequences used for genotyping are listed in Table 
2.1. The animals were housed in a pathogen-free environment with controlled temperature 
and humidity. Mice were maintained on a 12-hour light/dark cycle. Routine husbandry 
procedures included cage cleaning, feeding and watering and were conducted every other 
day. All procedures were performed in accordance with the animal protocol approved by 
the Institutional Animal Care and Use Committees of the University of North Carolina 
(IACUC). 
Calvarial Defect Model and Surgery procedures 
Mice at 9-11 weeks old (n=5-7) were anesthetized by intraperitoneal injection of 
ketamine/xylazine (124/8.8 mg/kg) (PSS, West Columbia, SC). After the incision region on 
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the head was shaved, skin was sterilized using 70% ethanol and betadine. A midline incision 
parallel to the sagittal suture was made using a scalpel in order to expose the parietal bones 
of the animal. A trephine bur attached to a dental handpiece was then used to create a 
defect with a diameter of 3.5 mm (Figure 2.2). Great caution was taken to minimize injury 
to the dura mater. An absorbable collagen sponge (diameter ≈ 4 mm, thickness ≈ 1 mm) 
(DuraGen, Integra, Plainsboro, NJ) containing saline or 500 ng rhBMP2 (Medtronic, 
Minneapolis, MN) was placed over the defect. The collagen sponge was molded into a disk 
shape (diameter ≈4 mm, thickness ≈1 mm) using a tissue biopsy punch. The skin was 
sutured using absorbable 4 or 5-0 chromic gut sutures (Ethicon, Somerville, NJ). Animals 
were allowed to recover on a heating pad before being transferred to clean recovery cages 
with soft bedding. Pain was managed using ketoprofen (5mg/kg, s.c) following surgery. Full 
time veterinarians were available at all times in the facility to ensure the health and care of 
the animals. All surgical procedures were approved by the Institutional Animal Care and Use 
Committees of the University of North Carolina (IACUC). 
Micro-CT imaging and analysis 
Separate groups of mice were euthanized 4 and 8 weeks following surgery, using 
CO2 asphyxiation followed by cervical dislocation. The heads were harvested and 
immediately soaked in 4% paraformaldehyde for 3 days at room temperature to achieve 
fixation. Calvarial defects of studied animals were scanned following fixation, using a μCT 
imaging system (Skyscan 1074HR, Aartselaar, Belgium) at a resolution of 20.5 μm/pixel. The 
following settings were used for the scan: X-ray voltage of 40 kVp and anode current of 
1000 µA for the 360 rotational steps. Scanned images were reconstructed using NRecon 
41 
 
software (Skyscan, Aartselaar, Belgium). Representative 3-Dementional images were 
created using CTAn and CTVol software provided by Skyscan.  
In order to compare the level of the healing between p65fl/+ and p65fl/+Osx-Cre mice, 
a parameter “healing ratio” was introduced into the analysis. This was defined as follows: 
Healing ratio= (1-[Current Volume of defect – Original Volume of defect]) X 100 percent. 
The volume of the calvarial defect was determined using ITK-SNAP (www.itksnap.org).  
Histology analysis 
For separate groups of animals, heads were harvested 4 and 8 weeks following 
surgeries. The tissue was immediately immersed into 4% paraformaldehyde for 3 days and 
then decalcified in 10% Ethylenediamine-tetraacetic acid (EDTA, Sigma, St. Louis, MO, USA) 
at pH 7.4 at 4 oC for 2 weeks. The samples were then dehydrated through a serial dilution of 
ethanol before paraffin embedding. The embedded samples were cut at the center of 
defect into 5 µm thick sections. Paraffin sections were then stained for Hematoxylin and 
eosin as well as Masson’s trichrome staining according to the manufacturer’s instructions 
(Sigma-Aldrich, St. Louis, MO). The stained sections were examined and photographed using 
a light microscope (Nikon Eclipse50i, Nikon, Melville, NY).  
Immunohistochemical analysis 
To evaluate the osteoblast differentiation between groups, immunohistochemical 
analysis was performed using a rabbit anti-BSP antibody (LF-84), kindly provided by Dr. Larry 
Fisher (NIDCR, Bethesda, MD). Briefly, paraffin sections of samples were deparaffinized in 
Hemo-D (Fisher Scientific, Waltham, MA) and then rehydrated through graded alcohol 
42 
 
(50%-100%). Antigen was retrieved by incubating specimens in 10 mM sodium citrate buffer 
(PH=6.0) for 20 minutes at 70 oC.  Endogenous peroxidase was quenched using 3% hydrogen 
peroxide in methanol. The slides were then incubated with primary antibody overnight at 4 
oC after blocking with 2.5% normal goat serum in 0.1% bovine serum albumin (BSA) for 30 
minutes at room temperature. The Avidin/Biotin Blocking Kit (SP-2001, Vector Laboratories, 
Burlingame, CA) was used to block all endogenous biotin and avidin binding sites present in 
tissues. A biotinylated secondary antibody was applied to the slides for 45 minutes at room 
temperature. The immunoreaction was amplified using RTU ABC Elite reagents (Vector 
Laboratories, Burlingame, CA). Finally, the slides were detected using DAB substrate kit 
(Vector Laboratories, Burlingame, CA) and then counterstained with hematoxylin (Sigma-
Aldrich, St. Louis, MO) and mounted. Non-specific rabbit IgG was used in place of a primary 
antibody for the negative control slides. The primary antibody was used at a 1:400 dilution 
and the secondary antibody was performed at 1:800 dilution in 2.5% goat serum in 0.1% 
BSA. Photographs of stained sections were taken using a Nikon Eclipse 50i microscope 
(Nikon, Melville, NY). 
CFU-F and CFU-OB assay 
Animals were euthanized at 13-14 weeks old. Following euthanisa, and the femur 
was separated from the tibia on both hind limbs. Skin and muscle were then carefully 
removed. A scalpel was used to cut the epiphysis of the long bones to expose the bone 
marrow cavity. Bone marrow stromal cells were isolated from femur and tibia by flushing 
the bone marrow with a 27G syringe (BD, Franklin Lakes, NJ). The cells were then seeded 
into 6-well plates (2 × 106 cells/well) in MesenCult™ MSC Basal Medium (STEMCELL 
43 
 
Technologies, Vancouver, British Columbia, Canada) supplemented with MesenCult™ 
Mesenchymal Stem Cell Stimulatory Supplements (STEMCELL Technologies), 2 mM L-
Glutamine and 100 units/ml penicillin/streptomycin. The medium was changed after 24 
hours to allow adequate adhesion of cells. For the CFU-OB assay, rhBMP2 (50 ng/ml, 
Medtronic) and 0.2 mM ascorbic acid were added into the culture as an osteogenic 
supplement (osteogenic medium). The medium was changed every 2 days for a period of 14 
days.  
After 14 days of culture, the cells were washed with PBS twice and then fixed with 
citrate-acetone-formaldehyde fixation solution for 1 minute. For the CFU-F assay, the cells 
were stained with 2.5% crystal violet for 20 minutes at room temperature.  Formation of 
osteoblastic colonies was detected using an alkaline phosphatase assay (Sigma-Aldrich, St. 
Louis, MO) according to the manufacturer’s instructions. Colonies containing more than 50 
cells were enumerated under a light microscope. 
Primary osteoprogenitors isolation 
The osteoprogenitor cells were isolated based on an established protocol (STEMCELL 
Technologies, Vancouver, British Columbia, Canada). Briefly, tibia and femur bones from 
adult mice (13-14 week old) were separated and trimmed to remove skin and muscle. Bone 
marrow was flushed away using a 27G syringe with HG-DMEM medium. A scalpel was used 
to slice the compact bone into fine pieces.  The bone pieces were incubated in 0.25% 
Collagenase Type I in PBS containing 20% FBS (STEMCELL Technologies) in a shaking 37 oC 
water bath for 45 minutes. Supernatant was collected and filtered through a 70 µm cell 
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strainer (Falcon, Corning Life Sciences). Collected supernatant was centrifuged at 300 x g for 
10 minutes at room temperature. The cell pellet was resuspended and maintained in HG-
DMEM regular growth medium (Lonza) until reaching 70% confluence. The medium was 
changed every other day.  
Total RNA isolation from tissue 
p65fl/+, p65fl/+Osx-Cre and Osx- Cre mice (N = 4-5 per group) were subjected to 
calvarial surgery. The rhBMP2 (500 ng) with the Absorbable Collagen Sponge (ACS) carrier 
was placed over the defect as described previously. After 4 weeks of surgery, mice were 
euthanized using CO2 asphyxiation followed by cervical dislocation. A trephine bur attached 
to a dental handpiece was used to remove the bony tissue in the defect area. Tissue 
samples were immediately flash-frozen in liquid nitrogen. The samples were kept at -80 oC 
until homogenization procedures. Specimens were homogenized using a mortar and pestle 
in liquid nitrogen. QIAzol lysis reagent (Qiagen, Valencia, CA, USA) was added into the 
powdered tissue for further homogenization and total RNA was then extracted using the 
Qiagen RNeasy Micro kit (Qiagen, Valencia, CA, USA) following the manufacturer’s protocol. 
RNA concentrations were measured with a Nanodrop ND-1000 spectrophotometer 
(Nanodrop, Wilmington, DE, USA) and total RNA was then submitted for quantitative real-
time PCR analysis. 
Quantitative real-time PCR 
Primary osteoprogenitors (P1-P3) isolated from animals were seeded into 12-well 
plates for overnight incubation. rhBMP2 (50 ng/ml, Medtronic), 0.2 mM ascorbic acid and 
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10 mM β- glycerophosphate were then added to cell cultures to induce osteogenic 
differentiation. The medium, with or without rhBMP2, was changed every other day. For 
separate groups of animals, total RNA was extracted using TriZol reagent (Invitrogen, 
Carlsbad, CA) after 4 and 7 days. Reverse transcription was completed using the SuperScript 
VILO™ cDNA Synthesis Kit (Invitrogen) according to the manufacturer’s instructions. 
Analysis by quantitative real-time PCR was conducted using Taqman Universal PCR Master 
Mix (Applied Biosystems, Foster city, CA) with the ABI Prism 7500 system. Standard, 
commercially available primers and probes for osteogenic markers were used: Sp7, Alp, Bsp 
and Satb2 (ABI assay No. Mm00504574_ml, Mm00475831_ml, Mm00492555_ml, 
Mm00507331_m1). The expression levels of target genes were standardized by 
housekeeping gene GAPDH (ABI assay No. 4308313) using the 2-ΔΔCt method (Livak and 
Schmittgen, 2001). 
Luciferase reporter assay 
To test the effect of TNFα on NF-κB activity, C2C12 cells were co-transfected with a 
NF-κB luciferase reporter (3xkB.luc), Renilla luciferase (pRL-TK, Promega, Madison, WI) and 
the Attractene transfection reagent (Qiagen, Valencia, CA, USA) in a 48-well plate. A pGL3 
plasmid was used as an empty vector control for 3xkB.luc.  After 24 hours of transfection, 
TNFα (Sigma-Aldrich) was added to the transfected cells at various concentration levels (0.1 
ng/ml, 1 ng/ml, 10 ng/ml and 100 ng/ml). Luciferase activity was determined using a Dual 
Luciferase assay (Promega) 12 hours following stimulation with TNFα according to 
established protocol. The transfection efficiency was normalized using renilla luciferase 
activity. The results were displayed as fold change. 
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Immunoblotting analysis 
A murine myoblast cell line, C2C12 cells (P11-P14) and primary osteoprogenitors 
(P1-P3) isolated from animals were seeded on 6- well plates in HG-DMEM (Lonza) 
supplemented with 10% FBS, 100 units/ml penicillin/streptomycin medium (regular growth 
medium). The cells were cultured overnight to allow cell adherence. A combination of 
rhBMP2 (50 ng/ml, Medtronic) and TNFα (10 ng/ml and 100 ng/ml, Sigma-Aldrich) was then 
added to the C2C12 culture. The protein was isolated using RIPA lysis buffer (Invitrogen) 
with a mixture of protease and phosphatase inhibitors at 1 and 2 hours following 
stimulation. For the primary osteoprogenitors, rhBMP2 was added to the culture and total 
protein was extracted after 15-, 30- and 60-minute intervals. 
Protein concentration was determined using a Bradford Protein Assay Kit (Bio-Rad, 
Hercules, CA). An equal amount of protein (15-20 ug) was then electrophoresed through 
10% SDS-polyacrylamide gel (SDS-PAGE) and transferred electrophoretically onto a 
polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA). The membrane was 
probed for targeted protein expression using primary antibodies after blocking with 5% 
non-fat milk for 1 hour at room temperature. The following primary antibodies were used: 
phosphorylated Smad 1/5/8, Smad 1, GAPDH and beta-actin (all from Cell signaling 
Technology). The membrane was then incubated with a horseradish peroxidase conjugated 
goat anti-rabbit antibody (Amersham Biosciences, Pittsburgh, PA) for 1 hour at room 
temperature. Signals were visualized using a chemiluminescent ECL prime kit (Amersham 
Biosciences). ImageJ software (http://imagej.nih.gov/ij/) was used to perform densitometric 
analysis. 
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Statistical analysis 
The experiments were performed in duplicate or triplicate for each time point and 
treatment. Data were expressed as mean ± SD. Difference among groups was determined 
using student t tests with SPSS software. Statistical significance was defined as p≤0.05. 
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Results: 
Effects of NF-κB haploinsufficiency on bone healing in a critical size calvarial defect model 
Micro-CT assessment of bone regeneration and image analysis 
In an attempt to investigate the role of NF-κB signaling in BMP2 mediated bone 
repair in the perspective of bone forming cells, we utilized transgenic mice with a deficiency 
in NF-κB in specific to the osteoblastic cell lineage. The p65fl/+Osx-Cre mice harbor both an 
Ostrix driven Cre transgene and a floxed p65 gene on one allele, leading to the ablation of 
p65 on osteoprogenitors. Calvarial defects were generated on p65fl/+Osx-Cre (n≥5) and p65 
fl/+ (n≥7) mice. An absorbable collagen sponge (ACS) containing rhBMP2 (500 ng), or saline 
as control, was implanted at the bone defect. The dosage of rhBMP2 (500 ng) was selected 
to effectively induce bone regneration based on previous ecotopic bone formation 
experiments performed by our lab (manuscript in preparation) as well as studies by other 
groups (Behr et al., 2012). To assess the level of new bone formation, micro-CT was 
performed at 4 and 8 weeks post-surgery. The level of calvarial healing in p65fl/+Osx-Cre 
mice was compared to that of p65fl/+ mice, which was used as littermate controls. For 
optimal interpretation of results, Osx-Cre mice at 4 weeks following surgery were also 
observed as a control. 
As shown in 3D resonstruction images, there was minimal or limited bone formation 
in ACS+saline at 4 (Figure 2.3) and 8 weeks (Figure 2.4) in the control group. At 4 weeks, no 
newly formed tissue was observed in p65fl/+Osx-Cre mice. The treatment with rhBMP2 
effectively enhanced bone healing in both controls and p65fl/+Osx-Cre mice. The Osx-Cre 
mice displayed a similar healing pattern as p65fl/+ mice at 4 weeks when treated with saline 
49 
 
or rhBMP2. At 8 weeks, extensively new bone formation was observed in the control group 
when treated with rhBMP2. However, p65fl/+Osx-Cre mice demonstrated decreased bone 
formation as compared to p65fl/+ mice in the rhBMP2 treated group at both time points.  
In order to quantitatively evaluate the level of bone healing, we utilized the 
percentage of the volume of newly regenerated bone tissue to the total defect volume as a 
parameter (healing ratio). The bone healing ratio of the p65fl/+Osx-Cre mice was significantly 
lower than that of the p65fl/+ mice when treated with saline (0 vs 0.21 at 4 week, p<0.01; 
0.11 vs 0.35 at 8 week, p<0.01) or BMP2 (0.42 vs 0.72 at 4 week, p<0.01; 0.45 vs 0.91 at 8 
week, p<0.01) (Figure 2.5).  At 4 weeks, the haploinsufficient animals showed significant 
reduction of bone healing (0 vs 0.17, p<0.01, saline group; 0.42 vs 0.77, p<0.01, rhBMP2 
group) as compared to Osx-Cre mice (Figure 2.5). The healing level in Osx-Cre mice at 8 
weeks following implantation was not tested in this study. Moreover, the healing level of 
Osx-Cre mice showed no difference (p>0.05) as compared to p65fl/+ mice at 4 weeks in both 
saline and rhBMP2 groups.   
It is important to note that there was no statistical difference in the bone repair 
level of p65fl/+Osx-Cre mice at 4 and 8 weeks in the rhBMP2 group, implicating a defective 
bone regeneration process in the absence of sufficient NF-κB signaling. The micro-CT 
analysis indicates that p65 haploinfficiency negatively affects rhBMP2 mediated bone 
formation during bone healing. 
Histological analysis of bone formation 
Histologically, the defect area was bridged mainly by large amount of fibrous tissue 
with an abundant infiltration of inflammatory cells in both animal groups without rhBMP2. 
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In some defect regions of p65fl/+Osx-Cre mice receiving saline, the residual collagen scaffold 
was clearly observed (Figure 2.6A, “S” indicates the residual collagen sponge). In the 
rhBMP2 group, moderate new bone formation was observed at 4 weeks, and extensive 
bony tissue was observed at 8 weeks. Consistent with the micro-CT findings, p65fl/+Osx-Cre 
mice revealed significantly less new bone formation in comparison with control animals. 
The defect area was markedly filled with connective tissue and few bone-like tissues, both 
at the periphery of native bones and in the center of the graft. Preosteoblastic like cells 
were found lining the newly formed bone tissue with osteocytes embedded within lacuna 
from H&E staining. Bone marrow-like structures with blood vessels as well as osteobclast-
like cells were identified in ACS with rhBMP at 8 weeks, indicating the presence of the bone 
remodelling process.  
Masson’s thrichrome staining was used to distinguish the unmineralized (osteoid) 
and mineralized bone matrix. Woven bone formation at the peripheral of the defect and 
also in the center of graft, was observed in the rhBMP2 group (Figure 2.6B).    
At 8 weeks, control animals treated with rhBMP2 demonstrated a high abundance of 
bone sialoprotein (BSP) (as shown by the dark brown immunohistochemical staining) in the 
newly formed bone at the peripheral defect (Figure 2.7B). In contrast, p65fl/+Osx-Cre mice 
treated with rhBMP2 demonstrated a weak/light stain, similar to the staining pattern 
observed in the control group treated ACS+ saline at 8 weeks (Figure 2.7A). BSP is a marker 
for osteoblastic differentiation and a nucleator for bone mineralization (Gordon et al., 
2007).  
CFU-F and CFU-OB analysis  
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The onset of bone injury stimulates the release and homing of multipotential stem 
cells from the bone marrow niche to the damaged sites for regeneration. Therefore, we 
intended to assess the number and osteogenic property of early and late osteoprogenitors 
within the bone marrow MSCs population (Chou et al., 2009).  
The CFU-F assay demonstrated that bone marrow stromal cells isolated from 
p65fl/+Osx-Cre mice showed a ~25% reduction of CFU-Fs as compared to the control animals 
(p65fl/+Osx-Cre vs p65fl/+, 44 vs 61 colonies/well, p<0.01). It is noteworthy that the number 
of CFU-OB colonies was decreased threefold in p65fl/+Osx-Cre mice as compared to the 
control group (p65fl/+Osx-Cre vs p65fl/+, 22 vs 56 colonies/well; p<0.01) (Figure 2.8B). When 
bone marrow stromal cells from Osx-Cre mice were used as another control, a statistically 
significant reduction of CFU-F colonies (p65fl/+Osx-Cre vs Osx-Cre, 44 vs 59 colonies/well, 
p<0.01) and CFU-OB colonies (p65fl/+Osx-Cre vs Osx-Cre , 22 vs 51 colonies/well, p<0.01) 
were observed in p65fl/+Osx-Cre mice. There was no difference observed in colony numbers 
between Osx-Cre and p65fl/+ mice. These obseravations implicate that fewer 
osteoprogenitors may be available to contribute to bone in mice with partially ablated p65 
expression. 
Effects of NF-κB haploinsufficiency on BMP2 mediated osteogensis in vitro 
One of the mechanisms by which BMP2 contributes to bone formation is via the 
regulation of osteoblastic differentiation. To understand whether the impaired bone 
regeneration directed by BMP2 in NF-κB haploinsufficient animal results from defective 
osteoblast differentiation, we evaluated the gene expression levels of osteoblastic markers 
using quantitative real-time PCR in both control and p65 haploinsufficient animals. 
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Osterix/Sp7 is a transcription factor that promotes the osteogenic lineage commitment as 
well as osteoprogenitor differentiation (Nakashima et al., 2002). It is regarded as an early 
marker for osteogenic differentiation. Alkaline phosphatase (ALP) and bone sialoprotein 
(BSP) are osteogenic markers corresponding to synthesis and maturation of extracellular 
matrix (Cowles et al., 1998; Harada and Rodan, 2003).  
In the absence of osteogenic supplements, osteogenic gene expression was 
comparable in both groups in all time points. With the addition of rhBMP2, there was 
significant mRNA upregulation of all osteoblast markers, in both animal groups, at day 4 
(Figure 2.9A) However, the expression levels of the Sp7, Alp and Bsp genes were markedly 
less in the cells of p65fl/+Osx-Cre mice at day 4 compared with those of p65fl/+ mice (p<0.05). 
Consistent with day 4 results, Alp and Bsp mRNA levels remained downregulated at day 7 
(p<0.05) (Figure 2.9B). As a result, the haploinsufficient mice displayed reduced osteoblastic 
differentiation.  This appears to be particularly evident at the early stages of osteoblastic 
differentiation (Figure 2.9A). 
To further investigate the cellular and molecullar events that occur during the bone 
healing process, we collected the RNA samples from the defect area after 4 weeks of 
implatation of ACS loaded with rhBMP2 (500 ng). The expression of osteogenic markers 
were evaluated using real-time PCR. At 4 weeks post-surgery when there was active bone 
regeneration present in the defect (Figure 2.6), the mRNA level of Sp7, Alp and Bsp were 
detectable in both animal groups. The p65fl/+Osx-Cre mice exhibited a statistically significant 
decrease in Sp7, Alp and Bsp expression as compared to the p65fl/+ mice (Figure 2.10). There 
was a 55% reduction of Sp7 expression in p65fl/+Osx-Cre mice as compared to p65fl/+ mice 
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(p<0.05) and over a 70% reduction as compared to Osx-Cre mice (p<0.01). Similarly, another 
early osteoblastic gene, Satb2, downstream of Runx2 was down-regulated by almost 60% in 
p65 insufficient mice as compared to p65fl/+ mice (p<0.01) and by 80% as compared to the 
Osx-Cre group (p<0.01) (Conner and Hornick, 2013; Dobreva et al., 2006).  
We also oberved an over 50% reduction in Alp mRNA expression in p65fl/+Osx-Cre 
mice as compared to both p65fl/+  (p<0.01)  and Osx-Cre mice (p<0.05). The expression of 
Bsp was also reduced in p65fl/+Osx-Cre mice as compared to p65fl/+ mice (p<0.05), but not 
Osx-Cre mice (p>0.05). These data implicate a trend  of increased expression of Sp7, Alp and 
Satb2 in Osx-Cre mice, as compared to p65fl/+ mice. However, there is no statistical 
significance detected between Osx-Cre and p65fl/+ mice. These results suggest that one 
possible mechanism by which bone healing is impaired in p65 haploinsufficient mice is the 
reduced preosteoblast population in the regenerated tissue. This may be caused by 
impaired osteoblastic differentiation of osteoprogenitors within the bone marrow reservoir 
of the p65fl/+Osx-Cre mice(Figure 2.9). Another possibility could be that the migration of 
progenitors in the p65fl/+Osx-Cre mice to injured sites is impaired or delayed. 
Effects of NF-κB haploinsufficiency on BMP2 mediated Smads phosphorylation 
Upon binding to the BMP2 receptor (BMPR) type I and II complex, BMP2 induces the 
phosphorylation of downstream Smad 1/5/8, leading to the transcriptional regulation of 
osteogenic related gene expression. It remains unknown whether or not the 
downregulation of osteoblastic markers expression in p65fl/+Osx-Cre mice was caused by the 
disruption of BMP2/Smad signaling axis. Osteoprogenitors isolated from control and 
p65fl/+Osx-Cre mice were treated with rhBMP2 (50 ng/ml) for various time courses (15-, 30- 
54 
 
and 60-minutes). Cell lysates were electrophoresed and then probed for anti-
phosphorylated Smad 1/5/8 and anti-Smad 1 antibodies. To evaluate the level of p65 
expression in cells, anti-p65 antibody was applied for detection. Immediately following 15 
minutes stimulation of rhBMP2, the osteoprogenitors isolated from p65 haploinsufficient 
mice displayed a 40-50% reduction of p65 production (Figure 2.11A-B).  
Cell lysates were electrophoresed and then probed for anti-phosphorylated Smad 
1/5/8 and anti-Smad 1 antibodies. As shown in Figure 2.11C-D , rhBMP2 at 50 ng/ml 
successfully induced Smad 1/5/8 phosphorylation following 15 minutes of treatment. Cells 
from p65fl/+Osx-Cre mice displayed decreased phosphorylation of Smad 1/5/8 levels at all 
time points following BMP2 stimulation (Figure 2.11C-D). The densotometric analysis 
further confirm that pSmad 1/5/8 levels were significantly reduced in osteoprogenitors 
from p65fl/+Osx-Cre mice (Figure 2.11D). These findings suggest that sufficient NF-κB 
signaling is crucial for the maintenance of a normal BMP2/Smad signaling axis. 
The effects of TNFα on BMP2- mediated Smads signaling in C2C12  
To further confirm our previous findings that there is an interaction between NF-κB 
and BMP2/Smads signaling, we treated C2C12 cells with TNFα and/or BMP2 and evaluated 
the phosphorylated Smads by immunoblot. TNFα is a pro-inflammatory cytokine and is well-
known as a potent activator for the NF-κB pathway. As shown in Figure 2.12A , TNFα was 
able to induce the transcriptional activity of NF-κB in C2C12 cells by the NF-κB luciferase 
reporter assay.  
In the absence of rhBMP2, TNFα (10 ng/ml and 100 ng/ml) alone did not affect the 
phosphorylation level of Smad 1/5/8. Upon the stimulation of rhBMP2 (50 ng/ml), there 
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was an increase in p-Smad expression. Of note, the addition of TNFα further enhanced 
Smads phosphorylation by rhBMP2 (Figure 2.12B). One consequence of this acute TNFα 
treatment and NF-κB activation is the enhancement of p-Smad abundance following BMP2 
signaling (Figure 2.12C). This is possibly caused by inceased Smad 1 expression induced by 
TNFα, followed by greater p-Smads abundance.  At 1 hour following stimulation, the level of 
p-Smads expression was further elevated as a result of the higher concentration of TNFα 
(100 ng/ml), whereas the Smad 1 level did not change. This may indicate that TNFα 
treatment may not only increase p-Smads expression via Smad 1 stimulation, but it may 
also directly enhance Smads phosphorylation. This will be further investigated in future 
studies. 
Taken together, the immunoblotting data (Figure 2.11-2.12) implicate that the 
relative absences of NF-κB in haploinsufficient animals results in reduced signaling along the 
Smad pathway. 
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Discussion 
The successful regeneration of BMP2 induced bone grafts requires a complex of 
signaling cascades which ensure sufficicient osteoconductivity and osteogenesis of 
osteoprgenitor cells (Carreira et al., 2014; Chenard et al., 2012). The importance of 
inflammatory signals in the regulation of bone regeneration processes has been addressed 
previously (Schmidt-Bleek et al., 2012). NF-κB is a central mediater in inflammation, making 
it an attractive target for researchers. Previous work in our lab has found that mice with 
insufficient p65 (a major NF-κB component) signaling in osteoblastic cells display retarded 
bone growth and development (manuscript in preparation) in a physiological context. In the 
current study, we further examine the effect of p65 haploinsufficiency on osteoblasts 
during bone healing in a calvarial defect mouse model. Critical-sized defects are defined as 
defects that can not be healed naturally during the life-time of an animal. Critical-sized 
animal models are a well-established tool for researchers to investigate bone healing 
processes (Szpalski et al., 2010). To the extent of our knowledge, this is the first study to 
show the effects of direct p65 ablation in osteogenic cell lines and its influence in bone 
regeneration in vivo.  
In the present study, we showed that rhBMP2-mediated healing processes in mice 
with a p65 haploinsufficiency are compromised, as demonstrated by a significant reduction 
in bony tissue regeneration as indicated by micro-CT analysis (Figure 2.3-5).  Bone 
regeneration in control animals displayed a physiological bone repair pattern  inflammation, 
fibrous tissue infiltration and bone matrix deposition (Cameron et al., 2013). Histological 
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evaluation further confirmed that p65 haploinsufficient animals illustrated a delayed and 
impaired healing process.  
CFU-F and CFU-OB assays are commonly used to assess the relative concentrations 
and osteogenic potential of mesenchymal stem cell (MSC) lineages within the bone marrow 
niche. MSCs are multipotential cells that possess the capacity to differentiate into several 
cell lineages such as osteoblastic, chondrogenic, adipogenic and myogenic lineages. The 
specification of stem cells into a cell lineage is regulated by many factors within the 
microenvironment. The expression of Runx2 and Sp7 genes drives stem cell commitment 
into osteoblasts while Sox9 drives a chondrogenic specification (Komori, 2006). Peroxisome 
proliferator-activated receptor gamma (Pparγ) and MyoD are the master genes that drive 
apiogenesis and myogenesis, respectively (Gang et al., 2004; Takada et al., 2010).  
In the current study, p65fl/+Osx-Cre mice demonstrated a comparable number of 
CFU-Fs, but significantly less CFU-OBs as compared to the control group (Figure 2.8). In 
response to rhBMP2, nearly 90-100% of the mesenchymal stem cells were shown to be 
osteogenic in p65fl/+ and Osx-Cre mice (Figure 2.8B). Only 50% of MSCs in p65fl/+Osx-Cre 
mice demonstrated osteogenic property. It is possible that the MSCs of p65fl/+Osx-Cre mice 
enter other lineages such as chondrogenic or adipogenic cell lineages. Fewer osteogenic 
progenitors within MSC populations in p65 haploinsufficient mice may lead to the impaired 
bone regeneration observed in the micro-CT (Figure 2.3-5) and histology analyses (Figure 
2.6).  
Furthermore, p65fl/+Osx-Cre  mice displayed significantly reduced expression of 
several osteogenic genes (bone markers) during rhBMP2 mediated repair at 4 weeks as 
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compared to both control groups (Figure 2.10). In accordance with the decreased mRNA 
expression levels for various bone markers, immunohistochemial analysis on bone defects 
demonstrated less BSP protein production after 8 weeks for both natural and rhBMP2 
mediated bone healing (Figure 2.7). These findings further suggest that the defective bone 
repair in p65fl/+Osx-Cre mice may be caused by the reduction in osteoprogenitors at regions 
corresponding to bone defects. The reduced osteoprogenitor populations may be caused by 
compromised osteogenic commitment of MSCs in p65fl/+Osx-Cre mice. Another possibility is 
defective migration of progenitors to regions of injury, as a result of insufficient p65.  
We next showed that the osteoblastic differentiation of osteoprogenitors in the p65 
haploinsufficient animals was impaired. Early osteogenic marker genes (Sp7, Alp and Bsp) 
were significantly downregulated in cells taken from p65fl/+Osx-Cre mice at 4 days following 
rhBMP2 treatment (Figure 2.9).  
rhBMP2 as an osteoinductive factor has been extensively used in bone regenrative 
therapy. Interestingly, we identified a mechanism by which NF-κB haploinsufficiency affects 
bone repair in the BMP2 signaling pathway. The BMP2 signaling pathway stimulates 
osteoblastic differention and mineralization by enhancing the expression of bone matrix 
proteins such as type I collagen, osterix, alkaline phosphotase, osteopontin and bone 
sialoprotein (Lai and Cheng, 2005; Matsubara et al., 2008; Rawadi et al., 2003). Our data 
demonstrated a downregulation of rhBMP2 mediated osteogenic differentiation in cells 
with insufficient NF-κB signals, suggesting a positive role for NF-κB in osteogenesis. 
Consistent with our findings, it has been previously reported that NF-κB activation and TNFα 
treatment induces osteogenic differentitaion and matrix mineralization in stem cells (Caron 
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et al., 2012; Cho et al., 2010; Feng et al., 2013; Hess et al., 2009; Li et al., 2014). Moreover, it 
was shown that the osteoblastic differentiation of mouse osteoblastic MC3T3-E1 cells 
(subclone 4) is regulated via NF-κB signaling (Kim et al., 2008).  
The BMP2 signaling pathway is regulated at multipal molecular levels. Signal 
stimulation is induced by binding of BMP2 ligands to the type I and type II receptor 
complexes, triggering intracelluar cascades (Carreira et al., 2014; Chenard et al., 2012).  R-
Smad proteins (Smad 1/5/8) are generally recognized as the primary components 
downstream of BMP2 signaling (Heldin et al., 1997; Miyazono et al., 2001). Phosphorylation 
and nuclear translocation of R-Smads induces the transcriptional modulation of genes 
responsible for osteogenesis (Chen et al., 2012; Retting et al., 2009). Two putative NF-κB 
response elements were found located in the promoter region of the BMP2 gene, 
implicating a direct regulatory mechanism of NF-κB in the BMP2 pathway (Feng et al., 
2003). Previous work in our lab also demonstrated that NF-κB induces BMP2 mRNA 
expression (manuscript in preparation). In the current study, we further demonstrated that 
the negative effect of NF-κB haploinsufficiency on osteogenic differentiation results from 
disruption of BMP2 induced Smad phosphorylation. To further comfirm the role of NF-κB in 
rhBMP2/Smad signaling, we tested Smad phosphorylation following stimulation of TNFα 
and rhBMP2 in a mouse myogenic stem cell line. Accordingly, we found that activation of 
NF-κB signaling by TNFα significantly enhanced rhBMP2 induced Smad phosphorylation.  
It is worth noting that previous studies suggest a negative role for NF-κB in 
osteogenesis, as demonstrated by bglap2-IKK-DN mice with decreased NF-κB function in 
osteoblasts and Col2-IKK2a mice with constitutively activated NF-κB signaling in early 
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progentors (Chang et al., 2009; Swarnkar et al., 2014). The discrepancy between our 
findings with previous work lies in the differentiation stage at which NF-κB function was 
manipulated in the animal model. In our study, the differentiation of primitive stem cells 
into osteoblasts was regulated by osteogenic genes in a definable temporal manner. Type 2 
collagen is expressed in early bipotential skeletal progenitors with a capability to 
differentiate into either a chondrogenic (with coexpression of Sox9) or an osteoblastic 
lineage (with further expression of Runx2 and Sp7 genes) (Rodda and McMahon, 2006). 
Osteocalcin is  generally accepted as a marker for mature osteoblasts, representing a final 
stage of osteoblastogenesis (Javed et al., 2010). The distinct outcome of bone formation in 
these animal models may indicate that the effect of NF-κB signaling on osteobalstic 
differentiation is stage-specific.  
In addition, previous work by our team indicates an obvious reduction of p65 in the 
p65fl/+Osx-Cre mice, while other subunits in the NF-κB pathway remain unaffected 
(manuscript in preparation). These results exclude the possibility of a compensation 
mechanism directed by other molecules.  Furthermore, the previous studies were 
established in a physiological context of bone development/homeostasis, while our current 
studies hereby tested the role of NF-κB in bone graft induced regeneration. The 
inflammatory phase following bone injury was suggested to be critical for progenitor 
recruitment, proliferation and further differention (Mountziaris and Mikos, 2008; 
Mountziaris et al., 2011; Schmidt-Bleek et al., 2012). Accordingly, we proposed NF-κB 
mediated inflammatory signaling as an indispensible factor in a pathological bone healing 
context. 
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In this study, we created a transgenic animal model with partial p65 ablation in 
osteoblastic cells without affecting other cell lineages that could contribute to bone repair. 
This strategy provided a way to elucidate the direct role of NF-κB signaling in cell signaling 
as it relates to bone formation. Using MSCs graft with an IKK small molecule inhibitor 
(IKKIV), Chang el al. (Chang et al., 2013) showed improved calvarial repair in rats, suggesting 
a negative role of NF-κB on bone repair. Bone defect sites are commonly infiltrated with an 
abundance of various cell types (e.g. osteobalstic cells, hematopoietic lineages, fibroblasts.) 
that may either have previously resided at the site pre-injury, or been recruited to the site 
post injury. It is possible that the application of inhibitors could influence some, or all, of the 
resident cells. It is therefore possible that distinct populations of cells at different injury 
sites or in different models could influence the study results. This is important to note for 
future studies and clinical applications.  
Successful bone repair is achieved by balanced cooperation of osteoblast-mediated 
bone formation and osteoclast-regulated bone resorption. Mechanistically the p65 ablation 
in p65fl/+Osx-Cre mice is restricted to osteoblastic cell lineages, and thus there was no direct 
effect on other cell types. However, other cells may have been indirectly affected. For 
example, osteoblasts are known to affect osteoclast expression and subsequent bone 
resoprtion (Sims and Martin, 2014). Osteoblasts directly regulate osteoclast maturation and 
activity by secreting RANKL and OPG. RANKL binds to its receptor RANK on osteoclasts and 
promotes osteocalstogenesis. In contrast, OPG counteracts RANKL-RANK mediated 
osteoclastogenic activity. This RANKL-OPG-RANK axis represents an essential regulatory 
mechanism by which osteoblastic cells affect osteoclast function (Boyce and Xing, 2008). 
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There is possibility that the defective osteoblastogenesis in p65fl/+Osx-Cre mice may 
influence osteoclast activity, thereby contributing to impaired bone healing. Previous 
studies in our lab, however, have shown that the number and activity of osteoclasts are not 
affected in p65fl/+Osx-Cre mice as compared to p65fl/+ mice (manuscript in preparation). Still, 
in future studies should address the role of osteoclastogenesis in bony defect and bone 
repair.  
Conclusion 
In summary, we proposed that NF-κB in osteobastic cells plays an important role in 
bone repair. As hypothesized, we found that intact NF-κB signaling is imperative for BMP2 
induced osteogenic differentiation of osteoprogenitors through canonical Smad pathways 
during bone healing. The current results demonstrate that in addition to playing a key role 
in osteoclastogenesis, NF-κB is necessary for for osteoblastogenesis. 
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Figure 2.1 Schematic pictures describing the generation of transgenic mouse model. 
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Figure 2.2 Illustration of the critical-sized defect model and procedures in mouse. 
(A) Schematic drawing of the calvarial defect mouse model. (B) A 4 mm diameter defect was 
made on the parietal bone of mice. 
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Figure 2.3 Micro-CT analysis of new bone formation in p65fl/+Osx-Cre, p65fl/+ and Osx-Cre 
mice at 4 weeks following surgery.  
Representative 3-D reconstruction images of parietal bones of each group at 4 weeks. Each 
group received either ACS (Absorbable collagen sponge) with saline or ACS loaded with 
rhBMP2 (500 ng).  
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Figure 2.4 Micro-CT analysis of new bone formation in p65fl/+Osx-Cre and p65fl/+ mice at 8 
weeks following surgery.  
Representative 3-D reconstruction images of parietal bones of each group at 8 weeks. Each 
group received either ACS (Absorbable collagen sponge) with saline or ACS loaded with 
rhBMP2 (500 ng).  
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Figure 2.5 Micro-CT analysis of new bone formation in p65fl/+Osx-Cre and p65fl/+ mice and 
Osx-Cre mice at 4 and 8 weeks following surgery.  
Quantitative assessment of regenerated bone volume of each group at different time 
points. Healing ratio= (1-[Current Volume of defect – Original Volume of defect]) X 100 
percent. (n= 5-8 animal/group; *P<0.05, **P<0.01) 
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Figure 2.6 Histological evaluation of healing process in calvarial defects in p65fl/+Osx-Cre 
and p65fl/+ mice.  
(A) Hematoxylin and eosin staining of newly formed bone. The samples were collected at 4 
and 8 weeks following implantation of absorbable collagen sponge (ACS) loaded with saline 
or rhBMP2 (500 ng). There is a lack of healing at 4 weeks in the saline-treated group for 
both animals. Specifically, no detectable bone tissue was found in the p65fl/+Osx-Cre mice. 
Increased mature bone tissue was demonstrated when treated with rhBMP2. p65fl/+Osx-Cre 
mice exhibited less new bone regeneration versus p65fl/+ mice. The upper panel of each 
group displays the sagittal sections of bone defects (2.5X magnification). The scale bar 
indicates 1000 um. The lower panels show enlarged views of the red rectangles in the upper 
panels (40X magnification, scale bar: 50 um). “S” indicates the residual collagen scaffold. (B) 
Masson’s trichrome staining of bone defect in both animal groups at 4 and 8 weeks post-
operation. (Upper panel: 2.5X, bar: 1000 um; Lower panel: 40X, bar: 50 um) 
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Figure 2.7 Immunohistochemical assessment of bone sialoprotein (BSP) expression in 
regenerated tissue of p65fl/+Osx-Cre and p65fl/+ mice. 
(A) Immunohistochemical staining of BSP in calvarial defect implanted with ACS+saline after 
8 weeks. (B) Immunohistochemical staining of BSP in calvarial defect implanted with 
ACS+rhBMP2 after 8 weeks. The right panel shows the negative IgG control. Arrow indicates 
the stained protein within the bone defect area. (Magnification: 40X, Scale bar: 50 um) 
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Figure 2.8 Colony-forming unit-fibroblasts (CFU-F) and colony-forming unit-osteoblasts 
(CFU-OB) were isolated and stained for p65fl/+Osx-Cre and p65fl/+ mice.  
Whole bone marrow stromal cells (2 X 106 cells/well) isolated from long bones of studied 
mice were plated onto 6-well plates. rhBMP2 (50 ng/ml) was used to induce osteogenic 
differentiation for the CFU-OB assay. (A) Representative culture plates of stained CFU-F and 
CFU-OB colonies. (B) Quantification of CFU-F and CFU-OB colony numbers. (N ≥ 5 animal per 
group; **P<0.01)  
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Figure 2.9 Relative mRNA expression levels of osteogenic markers (Sp7, Alp, Bsp) of 
osteoprogenitors obtained from p65fl/+Osx-Cre and p65fl/+ mice. 
Osteoprogenitor cells (105 cells/well) isolated from animals were seeded onto 12-well 
plates. rhBMP2 (50 ng/ml), 0.2 mM ascorbic acid and 10mM β- glycerophosphate was then 
added to cell cultures to induce osteogenic differentiation. (A) Expression levels at 4 days of 
culture (B) 7 days of culture with and without rhBMP2. Data are shown as mean ± SD. (N ≥ 5 
animal per group; *P<0.05, **P<0.01) 
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Figure 2.10 Relative mRNA expression levels of several osteogenic genes (Sp7, Alp, Bsp, 
Satb2) during the calvarial healing process in p65fl/+Osx-Cre and p65fl/+ mice. 
Quantification of mRNA expression of Sp7, Alp, Bsp and Satb2 in regenerated bone tissue 
after 4 weeks of implantation with ACS+rhBMP2 (500 ng) in mice. Data are shown as mean 
± SD. ( n= 4-5 animal/group; *P<0.05, **P<0.01) 
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Figure 2.11 The BMP2 mediated Smad signaling pathway is affected by NF-κB signaling.  
Osteoprogenitors from p65fl/+ and p65fl/+Osx-Cre mice were treated with/without rhBMP2 
(50 ng/ml) for 15 minutes, 30 minutes and 1 hour. (A) The expression of p65 in both animal 
groups after 15 minutes when treated with rhBMP2. (B) Relative expression of p65 was 
quantified using densitometry. (C) The expression of phosphorylated Smads (p-Smad 1/5/8), 
Smad 1 and GAPDH was examined by western blot. (D) Relative protein expression level of 
p-Smads to Smad 1. Generated by densitometry analysis using Image J. (*P<0.05, **P<0.01) 
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Figure 2.12 The BMP2 mediated Smad signaling pathway is affected by NF-κB signaling.  
(A) TNFα was able to enhance the transcriptional activity of NF-κB in C2C12 cells. (B) The 
expression of p-Smad 1/5/8, Smad 1 and β-actin in C2C12 cells upon treated with rhBMP2 
(50ng/ml) and/or TNFα for 1h or 2h. (+: TNFα 10ng/ml, ++: TNFα 100ng/ml) (C) Relative 
protein expression level of p-Smads and Smad 1 to β-actin at 1 hour and 2 hours. Generated 
by densitometry analysis using Image J. 
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Table 2.1 Primers used in PCR for genotyping. 
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CHAPTER 3 
GENE EXPRESSION ANALYSIS IN A CRANIAL BONE HEALING MODEL USING MICE WITH A 
NF-κB HAPLOINSUFFICIENCY 
 
 
INTRODUCTION 
Bony defects in the craniofacial skeleton have a large negative impact on society 
both economically and functionally (Amini et al., 2012; Baroli, 2009). Due to the complexity 
of bone repair, bone defects remain a challenging problem for surgeons and researchers. In 
order to enhance bone regeneration, autografts have been utilized as a golden standard for 
treating bony defects in clinical settings. Despite the advantages and non-immunogenic 
nature of autografts, the high cost and post-surgery patient morbidity have limited their 
application (Amini et al., 2012; Blokhuis et al., 2013). Recently, scientists have focused on 
the development of graft substitutes using synthetic scaffolds in a combination with growth 
factors or cells (Agarwal et al., 2009; Rahman et al., 2014). As a result of their strong 
osteoinductive capability, bone morphogenetic proteins hold great promise for tissue 
engineering application. BMPs belong to the transforming growth factor β (TGF-β) 
superfamily, which is involved in many biological processes including organogenesis, 
embryogenesis and wound healing. Elevated BMP2 expression has been observed in native 
craniofacial fractures (Farhadieh et al., 2004; Khanal et al., 2008). Moreover, previous work 
suggests a crucial role for BMP2 in the initiation and progression of bone fracture healing 
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(Kugimiya et al., 2005). Local delivery of BMP2 by an absorbable collagen carrier has been 
shown to enhance bone healing and regeneration in both experimental and clinical 
applications (Kim et al., 2005; Lin et al., 2013; Simpson et al., 2006). 
Accumulating evidence demonstrates the significant impact of the initial 
inflammatory response on bone regeneration following bone injury (Gerstenfeld et al., 
2003; Lu et al., 2013). Onset of injury induces enhanced acute expression of 
proinflammatory cytokines such as TNFα, IL-1β and IL-6 (Kon et al., 2001; Mountziaris and 
Mikos, 2008). The inflammatory signals then stimulate healing cascades by recruiting 
progenitor cells, thereby priming the environment for stem cell differentiation and 
angiogenesis (Mountziaris et al., 2011). Proinflammatory factors stimulate osteogenic 
differentiation of stem cells by increasing the productions of BMP2 (Fukui et al., 2003; Hess 
et al., 2009; Rifas, 2006). Accordingly, the maximal expression of BMP2 can be observed 
within 24 hours following injury. Further, the osteoinductive capability of BMP2 is impaired 
in the absence of proper inflammatory signals (Katavic et al., 2003; Zhang et al., 2002). 
These findings, taken together, suggest crosstalk between BMP2 mediated bone 
regeneration and the inflammatory signaling pathway. 
In an attempt to understand the relationship between inflammation and bone 
repair, our lab has been focused on NF-κB, a central mediator in the immune system and 
inflammatory process. Previously, by utilizing a genetically modified mouse model with a 
p65 (a major component of NF-κB signaling) haploinsufficiency, we demonstrated that p65 
partial ablation leads to delayed and defective calvarial repair. Further studies suggest that 
the mechanism by which NF-κB insufficiency negatively affects bone repair is through 
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disruption of osteoblastic differentiation via the BMP2/Smad pathway (Refer to Chapter 2). 
Our findings suggest that the integrity of the NF-κB mediated inflammatory signaling 
pathway in bone forming cells is vital for BMP2 induced bone regeneration. Consistently, 
other studies have demonstrated that NF-κB activation and TNFα treatment induces 
osteogenic differentiation and matrix mineralization in stem cells (Caron et al., 2012; Cho et 
al., 2010; Feng et al., 2013; Hess et al., 2009). Despite these large advances, the precise role 
of NF-κB in bone healing, along with the associated cellular and molecular pathways, 
remains unknown. This is a result of the complexity and intricacy of the bone repair process.  
Whole genome microarray analysis serves as a powerful tool that enables 
researchers to study gene expression and identify signaling pathways of interest on a large, 
genome-wide scale. Using microarray analysis, previous studies have investigated the gene 
expression patterns associated with fracture repair (Rundle et al., 2006). In this study, we 
sought to identify the differentially expressed genes during rhBMP2 mediated calvarial bone 
repair in p65fl/+Osx-Cre mice as compared to that of the p65fl/+ (control) group.  
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Materials and Methods 
Mice 
p65-floxed mice were crossed with Osterix-Cre mice to create mice with osteoblast-
restricted p65 ablation (p65fl/+Osx-Cre). p65 floxed mice (p65fl/fl) in which exons 5-8 were 
flanked with loxp constructs were provided by Dr. Albert S Baldwin of University of North 
Carolina at Chapel Hill (Steinbrecher et al., 2008). Osx-Cre mice, which express a GFP fused 
Cre recombinase gene downstream of the Osterix promoter, were purchased from Jackson 
Laboratory (Bar Harbor, ME). The Osx-Cre mice have been described in previous literature 
(Rodda and McMahon, 2006). All animals were on the C57BL/6 background.   
Cranial bone healing model 
Mice at 9-11s week old (n=5) were anesthetized using ketamine/xylazine (124/8.8 
mg/kg) by intraperitoneal injection. After heads were shaved, the skin was sterilized using 
70% ethanol and betadine. Next, a midline incision was made, parallel to the sagittal suture, 
with a scalpel, thereby exposing the parietal bone. A 4 mm diameter defect was then 
created using a trephine bur attached to a dental handpiece. Great caution was taken to 
minimize injury to the dura mater. An absorbable collagen sponge (diameter ≈4 mm, 
thickness ≈1 mm) (DuraGen, Integra，Plainsboro， NJ) containing 500 ng rhBMP2 
(Medtronic, Minneapolis，MN) was placed over the defect. The skin was sutured using 
absorbable 4 or 5-0 chromic gut sutures (Ethicon, Somerville, NJ). Animals recovered on a 
heating pad before being transferred to clean recovery cages with soft bedding. Pain was 
managed using ketoprofen (5 mg/kg, s.c) following surgeries. All procedures were 
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performed in accordance with protocols approved by the Institutional Animal Care and Use 
Committees of the University of North Carolina (IACUC). 
Total RNA isolation  
4 weeks following surgeries, mice were euthanized using CO2 asphyxiation followed 
by cervical dislocation. A trephine attached to a dental handpiece was used to remove bony 
tissue in the defect area. The tissue samples were immediately flash-frozen in liquid 
nitrogen. The samples were kept at -80 oC. Specimens were homogenized using a mortar 
and pestle in liquid nitrogen. QIAzol lysis reagent (Qiagen, Valencia, CA, USA) was added 
into the powdered tissue for further homogenization. Total RNA was then extracted using 
the Qiagen RNeasy Micro kit (Qiagen, Valencia, CA, USA) following the manufacturer’s 
protocol. RNA concentrations were measured using the Nanodrop ND-1000 
spectrophotometer (Nanodrop, Wilmington, DE, USA). RNA integrity was assessed using a 
Bioanalyzer (Agilent, Santa Clara, CA, USA). RNA samples with an RNA integrity number 
(RIN) score of 7.5 or higher were submitted for microarray analysis. 
Microarray analysis 
RNA samples were processed and hybridized onto Affymetrx arrays at the UNC 
genomic core facility (University of North Carolina at Chapel Hill). The GeneChip® WT PLUS 
Reagent Kit (Affymetrix, Santa Clara, CA) was used for cDNA synthesis from the total RNA. 
After amplification, synthesized cDNA were fragmented and labeled using the Affymetrix 
GeneChip Terminal Labeling Kit. Labeled cDNA fragments were then hybridized to the 
Affymetrix Mouse Gene 2.0 ST array (Affymetrix). The Affymetrix Mouse Gene 2.0 ST array 
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system has a comprehensive transcript coverage of 35240 total RefSeq transcripts and 
26191 well-established gene annotations, and utilizes an autoloader 
(http://www.affymetrix.com/catalog/131476/AFFY/Mouse+Gene+ST+Arrays#1_1). The 
arrays were washed and stained with R-phycoerythrin streptavidin in the GeneChip Fluidics 
Station 450 (Affymetrix). Arrays were scanned using the GeneChip Scanner 3000 7G Plus.  
The resultant image files (.CEL) were processed and analyzed using GeneSpring 
software v.12.6 (Agilent Technologies, Santa Clara, CA). Gene expression values were 
compared between the p65fl/+Osx-Cre and p65fl/+ (control) mice. To identify differentially 
expressed genes between p65fl/+Osx-Cre and control (p65fl/+) mice, unpaired t-tests were 
used, with Benjamini and Hochberg false discovery rate corrections. Statistical significance 
was defined as p<0.05. 
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Results: 
Microarray results 
Differential gene expression was not observed between p65fl/+Osx-Cre  and control 
(p65fl/+) mice. Possible explanations for this observation can be found in the Discussion 
section.  
Gene oncology analysis 
Genes that were either upregulated or downregulated with a fold change of 3 or 
greater were submitted for Gene Ontology (GO) analysis, which was performed using the 
GO Ontology Browser function provided by GeneSpring software. 55 GO terms satified the 
p-value cut-off of 0.05. The top 30 GO terms can be found in Table 3.3. 83 GO terms 
satisfied the corrected p-value cut-off of 0.05. 
Next, genes with a fold change of 1.2 or greater were examined. Among the over-
represented GO terms, two skeleton/bone related categories were identified: Regulation of 
Ossification (p=0.0001) and Regulation of Biomineral Tissue Tevelopment (p=0.0238). There 
were 54 genes identified in the Regulation of Ossification category (Tables 3.4-3.5) and 9 
genes identified in the Regulation of Biomineral Tissue Tevelopment category (Table 3.6). A 
complete list of identified genes in each category can be found in Tables 3.4-6. The p-value 
listed for each GO term represents a relative enrichment in frequency for that GO category. 
p65fl/+Osx-Cre mice demonstrated decreased BMP (BMP4, BMP6, BMP7) expression 
as compared to the p65fl/+ group (Table 3.4). The BMP family has over 17 other members, 
including BMP4, 6 and 7. Due to their osteogenic capability of inducing ecotopic bone 
formation, these members are commonly recognized as osteogenic BMPs (Bragdon et al., 
91 
 
2011). A reduction in levels of osteogenic markers osterix (Sp7), alkaline phosphotase (Alp) 
was also obeserved in p65fl/+Osx-Cre mice.  
 Additionally, other osteogenic genes were downregulated in mice with a p65 
haploinssuficiency (Tables 3.4-6). Wnt element(low-density lipoprotein receptor-related 
protein 5 (Lrp5) is important for maintaining bone mass. The glycoprotein m6b (Gpm6bA) 
gene encodes a membrane glycoprotein that serves as regulator of osteoblast function and 
bone formation (Drabek et al., 2011). Dlx5 is a key regulator for bone formation (Levi and 
Gitton, 2014). p65fl/+Osx-Cre elicited less Dlx5 and Gpm6bA expression, suggesting impaired 
bone mineralization. Special AT-rich sequence-binding protein (SATB2) is a potent 
transcription factor that is critical for skeletal development and osteoblastogenesis 
(Dobreva et al., 2006). It interacts and synergizes with other osteogenic transcription factors 
such as runx2 and osterix,  robustly enhancing their transcriptional activity to promote 
osoteogenesis (Zhang et al., 2011). Satb2 overexpresion has been shown to induce 
osteoblastic differentiation in vitro and also promote bone regeneration in vivo (Gong et al., 
2014a; Gong et al., 2014b).  
In addition, several genes related to bone formation and remodelling were increased 
in p65fl/+Osx-Cre including BMP3 and Extracellular matrix protein 1 (Ecm1) (Table 3.5). Ecm1 
is a secreted glycoprotein that negatively regulates endochondral bone formation through 
inhibition of alkaline phosphotase activity and mineralization (Deckers et al., 2001). BMP3 is 
a negative regulator for bone morphogenesis and development (Daluiski et al., 2001). BMP3 
lacks a cystein residue, which is normally responsible for BMP dimerization. BMP3 serves as 
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BMP antagonist and competes with other osteogenic BMPs for receptor binding (Rosen, 
2006).  
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Discussion: 
In the present study, RNA samples were taken from bone tissue that has been 
regenerated at calvarial defects in both p65fl/+Osx-Cre and p65fl/+ mice. A genome wide 
microarray analysis was utilized for samples in an attempt to identify differentially 
expressed genes, along with downstream signaling pathways that are associated with bone 
repair. No genes were differentially expressed between groups when using a p-value cut-off 
of 0.05. There are, however, several explanations for this outcome. 
The bone repair process involves in a series of overlapping events that initiate from 
an acute inflammatory phase, which lasts for 1-3 days. A combination of intramembranous 
ossification and endochondral ossification occur subsequently, beginning at 7-14 days 
following injury. Bone remodeling takes place beginning approximately 10 days and lasting 
at least 28 days following injury (Ai-Aql et al., 2008; Khan et al., 2008; Kon et al., 2001). The 
vigorous renewal phase in bone regeneration is associated with great amount of signaling 
cascades, as compared to the much quieter remodeling phase, which involves significantly 
less pathways (Khan et al., 2008). A previously reported, relevant study evaluated the 
expression pattern of transcription factors during bone repair in rat, using microarray 
analysis based on 1254 probe sets. The number of significant transcription factors peaked at 
Day 5, and gradually decreases to minimal basal levels at Day 56, following injury (Wise et 
al., 2010). Taken together, these previous findings suggest that the dramatic bone 
regeneration process occurs in the first 2 weeks following bone injury (Hadjiargyrou et al., 
2002). 
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In a previous investigation, we observed decreased bone repair (reflected by the 
healing ratio using micro-CT) in p65-ablated mice implanted with ACS+rhBMP2 (0.72 vs 0.42 
at 4 week, p<0.01), as compared to controls. The healing level in the control group slightly 
improved to 0.91 at 8 weeks. In accordance with the temporal bone healing phases 
described previously, the control group demonstrated a greater regeneration within the 
first 4 weeks, with mild enhancement in the following 4 weeks. Interestingly, the p65 
haploinsufficient mice did not improve significantly (0.42 vs 0.45, p>0.05) from 4 weeks to 8 
weeks. These findings suggest a very likely possibility that the selective time point (4 weeks 
post surgery) exceeds the time frame when the most active bone regeneration occurs. At 4 
weeks, the biological and molecular events associated with bone repair remain at a lower 
level than typical for the bone defect model. Fewer participating signaling pathways could 
be one explanation for the resulting outcome. Furthermore, the precise mechanism by 
which NF-κB signaling affects osteoblast expression is yet to be elucidated. It is possible that 
NF-κB signaling pathway is essential for osteoblastic cells in an early phase (e.g. before 4 
weeks) during repair in our bone defect model.  
In this study, we studied gene expression in five experimental p65fl/+Osx-Cre mice 
and four control p65fl/+ mice. The sample sizes may be too small to achieve adequate 
statistical power. Additionally, we observed a high variation within sample replicates for 
each group during the microarray analysis. As shown in Figure 3.1, the replicates varied and 
scattered for both the control and experimental groups. Each animal in its respective group 
(either control or p65 haploinsufficient) was regarded as a replicate. Each replicate shared 
the same genetic background and underwent the same experimental treatment.  Since the 
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replicates of one group represent similar experimental conditions, they are assumed to be 
similar to values within the same group, and different than values in the other group. High 
biological variation among sample replicates could be another reason for the observed 
failure to gain statistically significant results. 
In summary, using a global survey of gene expression using microarray analysis, no 
differential gene expression was observed between p65fl/+Osx-Cre and p65fl/+ mice. Three 
possible explanations for this outcome include that 1) the selected time point may be 
beyond the timeframe for occurrence of dramatic biological bone repair events, 2) the 
number of samples may not be sufficient to achieve statistical significance and 3) large 
variations among sample replicates within groups may have affected the results. Still, the 
current results implicate an obvious trend, demonstrating that mice with a p65 
haploinsufficiency express lower levels of osteogenic genes, including osteogenic 
differentiation markers as well as key mediators involved various osteogenic signaling 
pathways (BMPs, Wnts, etc.).  
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Table 3.1 Gene downregulation observed in p65fl/+Osx-Cre mice at 4 weeks. 
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Table 3.2  Gene upregulation observed in p65fl/+Osx-Cre mice at 4 weeks. 
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Table 3.3 Gene Ontology Results for in p65fl/+Osx-Cre mice (Terms with Fold Change > 3). 
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Table 3.4 Gene Downregulation of the GO Regulation of Ossification Category in 
p65fl/+Osx-Cre mice (Fold Change > 1.2). 
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Table 3.5 Gene Upregulation of the GO Ossification Category in p65fl/+Osx-Cre mice (Fold 
Change > 1.2). 
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Table 3.6 Gene Dysregulation of the GO Regulation of Biomineral Tissue Development 
Category in p65fl/+Osx-Cre mice (Fold Change > 1.2). 
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Figure 3.1 Sample Quality Control 
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Figure 3.2 A schematic of temporal gene expression profiling during the bone healing 
process. 
 
 
Adapted from Ai-Aql et al., 2008; Hadjiargyrou et al., 2002; Khan et al., 2008; Kon et al., 
2001 
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CHAPTER 4  
GENERAL DISCUSSION 
Bone defect is a significant healthcare problem that largely jeopardizes general 
social welfare. In the United States, over 2.5 billion dollars are used to treat patients with 
bone defect annually (Amini et al., 2012; Baroli, 2009). There is an urgent need for the 
development of efficient treatments for bone defect that integrate bone repair and 
regeneration techniques.  
While many investigations demonstrate an inhibitory effect of inflammation on bone 
formation (Pape et al., 2010; Thomas and Puleo, 2011), short-term exposure of 
inflammation can actually enhance osteogenesis. Previous studies show that pro-
inflammatory cytokines including TNFα, IL-1 and IL-6 increase BMP synthesis and induce 
osteogenic differentiation of chondrocytes and human mesenchymal stem cells (Fukui et al., 
2003; Rifas, 2006). Local administration of TNFα during the early stages of injury accelerates 
fracture healing in vivo, suggesting that pro-inflammatory cytokines play important role in 
the initial osteogenic differentiation of progenitors involved with bone healing (Glass et al., 
2011). Accordingly, the absence of sufficient inflammatory signals results in impaired bone 
healing in animal models (Gerstenfeld et al., 2003; Katavic et al., 2003; Zhang et al., 2002). 
Further, application of anti-inflammatory medication to patients with long bone fracture 
increases the risk of nonunion, malunion and infection 
110 
 
(Bhattacharyya et al., 2005; Jeffcoach et al., 2014). These seemingly contradicting results 
raise many questions regarding the effects of inflammation on wound repair.  
NF-κB is a central mediator of inflammation and the immune response, and is 
therefore an attractive target for investigating the role of the inflammatory reaction in bone 
repair. NF-κB signaling pathway has long been known to regulate the function of 
hematopoietic stem cell (HSC) derived cell lineages (e.g. T cell, B cells, monocytes.) (Stein 
and Baldwin, 2013). Accumulating research suggests a role for NF-κB in MSC modulation. 
NF-κB signaling regulates stem cell fate by targeting expression of critical transcription 
factors. NF-κB also functions as an inhibitor of chondrogenesis (Sitcheran et al., 2003) 
myogenesis (Langen et al., 2001) and adipogenesis. However, the effect of NF-κB on 
osteogenesis is not well studied and the current knowledge of this interaction is 
controversial.  
We and several other groups have suggested a positive effect of NF-κB on 
osteogenic differentiation of stem cells including hMSCs and human stem cells derived from 
apical papilla (Caron et al., 2012; Cho et al., 2010; Feng et al., 2013; Hess et al., 2009; Li et 
al., 2014). In contrast, several other studies have indicated a negative role of NF-κB on 
osteogenesis (Chang et al., 2009; Swarnkar et al., 2014). Given that they employed 
transgenic mice with manipulated NF-κB function on osteoblasts in a later or earlier stage 
then the one studied by our group, one possible explanation for the discrepancy is that the 
role of NF-κB is dependent on the stage of differentiation. Furthermore, the observations 
made by other groups were based on the results of manipulating NF-κB regulatory elements 
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such as IκB kinase. The effect of this manipulation could possibly extend to several other 
NF-κB components or subunits sharing the same modulators as NF-κB/p65.  
In this study, we generated a p65 conditional knock down mouse with p65 
haploinsufficiency restricted to preosteoblasts, by crossing p65 floxed mice with Sp7 driven 
Cre mice. In this model, NF-κB was impaired at an early stage of osteoblastic differentiation 
in the Sp7 expressing cell lineage. Direct targeting of p65, a major component of the NF-κB 
signaling pathway, ensured that other subunits of the NF-κB pathway were not affected. 
This model enabled the study of the direct influence of p65 in early osteoblastogenesis 
during bone repair.   
In the present study, the healing process in p65fl/+Osx-Cre mice was impaired or 
delayed as shown by the micro-CT analysis and histological assessments. We next sought to 
elucidate the underlying mechanisms by which p65 influences osteogenesis.  
Bone is able to self-repair without formation of scar tissue through a process that 
recapitulates the natural bone development of both intramembranous and endochondral 
bone (Dimitriou et al., 2011; Einhorn, 1998). Bone repair is a well-defined and strictly 
orchestrated process where many cellular and molecular events take place in order to 
regenerate new bone. These complex events occur in overlapping phases including MSC 
recruitment, proliferation, differentiation and bone remodeling.  
The initial step to obtaining successful regeneration is the recruitment of sufficient 
amounts of MSCs and progenitor cells to the site of injury (Schmidt-Bleek et al., 2012). MSCs 
are stem cells that can further differentiate into osteoblasts. The presence of MSCs in the 
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bone healing process is critical for the outcome of bone repair due to its ability to modulate 
inflammation and its stimulatory effect on tissue regeneration. Various cell types, such as 
endothelial and immune cells, produce a broad spectrum of inflammatory cytokines and 
matrix proteins within minutes of bone trauma (Mountziaris and Mikos, 2008; Mountziaris 
et al., 2011). In response to these chemoattractants, MSCs from local sources (e.g. 
periosteum, muscle and local bone marrow) and circulating MSCs migrate to injured sites 
(Maxson et al., 2012).   
Bone marrow contains primitive MSCs that can be recruited to bone defects for 
repair following trauma. In the present work, p65fl/+Osx-Cre mice showed less CFU-F 
colonies, whereas the CFU-OB colonies were dramatically reduced, as compared to both 
control groups (p65fl/+ mouse and Osx-Cre mice). MSCs from p65fl/+Osx-Cre mice showed 
less osteogenic potential in response to rhBMP2.  Fewer osteoprogenitors within the bone 
marrow reservoir in p65 haploinsufficient mice, possibly contributing to the defective bone 
repair processes. Furthermore, in p65fl/+Osx-Cre mice, fewer preosteoblasts displayed 
expression of early bone repair markers within the regenerated tissue 4 weeks following 
rhBMP2 application. Previous research in our lab demonstrates that the cell proliferation 
rate in p65 haploinsufficient mice is not different from that of the control group. MSCs are 
multipotent stem cells that can develop into a variety of cells, including adipocytes and 
chondrocytes. Instead of osteogenic specification, MSCs in mice with the p65 
haploinsufficiency may be predisposed to an adipogenic or chondrogenic specification.   
The migration of MSCs induced by secreted chemoattractants at the site of injury 
also plays an important role in bone healing. The migration capability of these progenitors 
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influences the outcome of bone repair. In an attempt to investigate the broader effects of 
the p65 haploinsufficiency on rhBMP2-induced osteoblastic differentiation, we evaluated 
the gene expression profile of bone defects 4 weeks following rhBMP2-induced bone repair. 
Although no statistically significant genes were identified in p65fl/+Osx-Cre mice as 
compared to the control animals (p65fl/+ mice), we still observed upregulation of several 
genes that are responsible for chemotaxis and cytoskeleton modulation (Table 3.2). 
Furthermore, we also found that several osteogenic genes were downregulated in p65 
haploinsufficient mice (Table 3.4).  
In order to regenerate new bone, the recruited MSCs undergo osteogenic 
differentiation into osteoblasts, which then produce bone matrix and promote 
mineralization. Resembling bone morphogenesis during embryonic development, new bone 
is formed through intramembranous and endochondral ossification. During 
intramembranous ossification, primitive MSCs directly differentiate into osteoblasts. In 
endochondral ossification, MSCs first differentiate into chondrocytes and produce a 
cartilage template, which osteoblasts later replace with bone tissue (Javed et al., 2010). 
Differentiation of MSCs into mature osteoblasts requires sequential expression of many 
transcription factors and matrix proteins.  
Owing to their pivotal role in osteoblastogenesis, these factors are commonly 
referred to as bone markers. Runx2 and osterix are key transcription factors that promote 
an osteogenic lineage commitment as well as osteoprogenitor differentiation during early 
osteogenic differentiation (Nakashima et al., 2002). Alkaline Phosphatase (ALP) and Bone 
Sialoprotein (BSP) are early osteogenic markers important for synthesis and maturation of 
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extracellular matrix. Osteocalcin (OCN) is a definitive marker of terminally differentiated 
osteoblasts (Maxson et al., 2012). Biochemical and biomechanical cues within the 
microenvironment regulate bone formation via bone precursors and various intracellular 
and extracellular molecular pathways. Wnt, TGF-β, BMP, VEGF and MAPK signaling 
pathways have been implicated in osteogenic differentiation of MSCs (Allori et al., 2008). 
Although many key players have been identified, the complex interaction and crosstalk 
between the various signaling cascades remains only partially understood.    
We demonstrated that osteoprogenitors isolated from bone marrow of p65fl/+Osx-
Cre mice displayed compromised osteoblastic differentiation with a corresponding decrease 
in the expression of several osteogenic genes (Sp7, Alp, Bsp). This appears to be particularly 
evident during the early stages of differentiation.  These data are consistent with 
microarray results that demonstrated downregulation of Sp7, Alp and Stab2 in p65fl/+Osx-
Cre mice. Together with data from previous studies, this suggests that NF-κB signaling plays 
a distinct role in different stages during osteoblastogenesis. Our data hereby support that 
sufficient NF-κB function is required for early osteoblastic differentiation. 
The BMP2/Smad signaling pathway is a key regulator of osteoinduction and 
osteogenesis. Smads, which are immediately downstream of BMP2, mediate many 
osteogenic cascades. In our study, the immunoblotting demonstrated that rhBMP2-induced 
phosphorylation of Smads was impaired in p65fl/+Osx-Cre mice. Further, C2C12 cells with 
intact NF-κB function demonstrated increased p-Smads expression following activation by 
acute TNFα. One consequence of acute TNFα treatment and NF-κB activation is the 
enhancement of p-Smads abundance following BMP2 signaling.  The Increased p-Smads 
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abundance may also result from enhanced Smad 1 expression following the TNFα 
application. In summary, the relatively low NF-κB levels observed in the p65 
haploinsufficient animals likely causes reduced signaling along the Smad pathway. 
Recent studies in this field discussed concerns regarding the unexpected skeletal 
abnormalities of Osterix-Cre mice, which could possibly confound the results of bone 
studies utilizing this model (Chen et al., 2014; Huang and Olsen, 2015; Wang et al., 2015). 
These findings were based on the observations of bone phenotypes during physiological 
bone development in pups or young mice, without investigation of the bone healing and 
regeneration mechanisms. Here, we demonstrated that Osx-Cre mice possess comparable 
bone repair processes to that of the p65-floxed control mice. We did not observe any 
defective healing in the Osx-Cre mice during natural or rhBMP2 induced bone repair at 4 
weeks. The healing level was significantly decreased in p65 haploinsufficient mice as 
compared to the Osx-Cre mice. Further, Osx-Cre mice displayed a similar relative 
percentage of MSCs and osteoprogenitors within whole bone marrow stromal cells (CFU-Fs 
and CFU-OBs) as compared to the p65-floxed control mice. Enhanced osteogenic gene 
expression was also observed in Osx-Cre mice during bone healing, implying the presence of 
an active bone regeneration process. Our data therefore suggest that the absence of p65 
function primarily contributes to the compromised bone healing in p65 haploinsufficient 
mouse.  
In conclusion, we have demonstrated that mice with ablated p65 function have 
decreased efficinecy of bone repair. Cells of p65fl/+Osx-Cre mice have fewer CFU-OBs as well 
as decreased Sp7, Alp, Bsp and Satb2 expression, indicating defective osteoblastogenesis. 
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The adverse effect of the p65 haploinsuffiency on osteoblastogenesis and bone repair can 
be attributed to the diminished canonical Smad pathway. These data suggest that intact NF-
κB is essential for osteoblastogenesis during the bone healing process.  
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